Finex logo
Finex Intelligence

Market Signal Briefing

Real-time pulse of financial headlines curated from 2 premium feeds.

Last news saved at Mar 14, 16:46 40m ago Cron last ran Mar 14, 16:46 40m ago 2 sources live
Switch language
83,846 Stories ingested Auto-fetched market intel nonstop.
386 Distinct tickers Symbols referenced across the feed
stockne... Trending sources stocknewsapi • cryptonews
Hot tickers
BTC XRP ETH USDC $TRUMP SOL
Surfacing from current coverage
Details Saved Published Title Source Tickers
2026-02-23 14:09 19d ago
2026-02-23 09:00 19d ago
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination stocknewsapi
FEMY
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --

ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to this first-step infertility treatment option.

“The creation of a new Category III code for the FemaSeed ITI procedure reflects the innovation and differentiated approach of our technology,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “As we initiate the rollout of FemaSeed to gynecologists and their clinical teams, supported by the availability of our FemSperm® product line, we intend to expand our provider footprint, accelerate adoption, and increase access to care for more than 10 million women in the U.S. affected by infertility. Together, these offerings advance our scalable commercialization strategy and position us for sustainable long-term growth.”

FemaSeed is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Developed to bridge the gap between traditional intrauterine insemination (IUI), which often has low success rates, and in vitro fertilization (IVF), which is costly and invasive, FemaSeed offers a safe, effective, accessible, and cost-efficient first-line, in-office treatment option. In its pivotal clinical trial (NCT0468847), conducted in the challenging setting of low male sperm count, FemaSeed achieved more than double the pregnancy rates of IUI.1 FemaSeed is authorized for use in the U.S., Europe, UK, Canada, and Israel. Learn more at www.femaseed.com.

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1

FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, [email protected]
Nathan Abler, Dresner Corporate Services, (714) 742-4180, [email protected]
2026-02-23 14:09 19d ago
2026-02-23 09:00 19d ago
New Jeep Cherokee set to lead Stellantis' U.S. sales turnaround stocknewsapi
STLA
LOS ANGELES – Stellantis is counting on the return of the Jeep Cherokee to help lead a U.S. turnaround for the SUV brand and embattled automaker.

The Cherokee returns after a three-year hiatus, rejoining the compact and midsize vehicle markets, which represent the largest segments in the U.S. It also marks Jeep's first traditional hybrid model and its most fuel-efficient, gas-powered vehicle ever in the U.S.

"This is a critical vehicle for us," Richard Cox, Jeep senior vice president of brand operations, told CNBC during a media event for the 2026 Cherokee. "I think this expands our reach with this level of powertrain, with this level of fuel efficiency and capability."

The vehicle is currently arriving in U.S. dealerships as arguably the most important U.S. launch for the automaker this year. Stellantis is attempting to regain market share after significant losses in recent years.

The automaker has set a target to increase retail sales by roughly 25% in 2026 to 1.15 million vehicles, driven by updated and new models as well as pricing and product realignments to move vehicles off dealer lots.

"It's a huge part of our growth," Cox said regarding the new Cherokee. "It positions us well in '26."

Last year, Jeep narrowly reported its first annual sales increase – up less than 1% – since 2018, when the brand achieved sales of more than 973,200 units. That compares with sales of 593,401 Jeeps in 2025, a 39% decline over the seven-year period.

The 1% annual sales growth for Jeep wasn't enough to lift Stellantis' overall U.S. sales into the black for the year, though. The parent company reported a 3% decline in U.S. sales in 2025 – marking its seventh consecutive fall amid a failed push into all-electric vehicles and significant cost cutting and price increases under former CEO Carlos Tavares.

Sean Hogan, a Los Angeles-area dealer who's leading Stellantis' franchised national dealer council, believes the 25% target increase in U.S. sales is achievable with the company's new leadership and product slate.

"We've been missing Cherokee. It's huge to us. It's huge to Jeep, and I think they nailed it," said Hogan, vice president of Sierra Auto Group. "It's key for us to getting the machine turned back on to start the volume that's going to be flowing again and generate the capacity in our dealerships. It's bringing in new customers."

Jeep Cherokee is priorityJeep believes it has a winner with the Cherokee, even more so than the last generation of the vehicle that peaked at nearly 240,000 units sold in 2018.

The company declined to discuss production expectations, but it likely won't be able to achieve similar sales numbers until the company adds U.S. output capabilities. Plans to expand production at an Illinois plant are expected as early as next year.

The Cherokee is currently only being produced at a plant in Toluca, Mexico, that also manufactures a smaller Jeep Compass SUV and Jeep Wagoneer S EV, and is slated to produce the upcoming Jeep Recon EV as soon as the second quarter.

Stellantis' Toluca plant is estimated to have the capacity to produce 303,000 vehicles annually, according to AutoForecast Solutions.

The auto intelligence and forecasting firm expects Jeep's U.S. sales this year to increase roughly 10% to 650,000 units, led by the Cherokee, according to Sam Fiorani, AFS vice president of global forecasting.

Read more

Jeep CEO Bob Broderdorf told CNBC in December that Cherokee is the priority for the brand amid slowing EV sales.

"Once Cherokee is done and has a good run rate, then we can start on Recon," he said. "Recon, I'm not in a hurry. I want to get the quality right of Cherokee, and then as soon as we're confident, OK, turn on the Recon."

Broderdorf has been leading a turnaround strategy for Jeep since being named CEO in February. Those efforts have included significantly reducing prices and model complexity and shifting away from the brand's all-electric plans as part of a broader pullback by Stellantis that will cost the company $26 billion.

2026 CherokeeThe 2026 Cherokee is a traditional hybrid – a technology pioneered by the Toyota Prius – that does not require a plug, but does use a small battery and electric motors to assist fuel economy.

Jeep has historically been known for its large, boxy gas-guzzling SUVs, but the Cherokee is expected to achieve 37 combined miles per gallon, including 35 mpg on the highway and 39 mpg in the city.

"Those are very competitive numbers," said Mike Cockell, director of Jeep Cherokee nameplate. "It's a vehicle that must do it all for the customer, and we feel we're able to do it all. It's like a Swiss army knife."

The updates are an attempt to make the vehicle more competitive against brands such as Toyota as well as to capitalize on expected growth in hybrid vehicles.

"Electrification trends are pretty flat. Hybrid trends are absolutely growing," Cox said. "So, I think it was a big move in the right direction."

The Cherokee features a 1.6-liter turbocharged, four-cylinder hybrid powertrain rated at 210 horsepower and 230 foot-pounds of torque. It features standard four-wheel drive, relatively large interior screens, and 140 standard and available safety and security features.

Starting pricing for the Cherokee ranges from roughly $37,000 to $46,000, according to Stellantis. The bestselling model is expected to be the $39,995 Cherokee Laredo, which Stellantis says is projected to represent 36% of the vehicle's sales.

The pricing positions the midsize vehicle to be competitive in its own segment as well as against compact SUVs such as the Toyota RAV4 and Honda CR-V.

Jeep officials say those two brands served as benchmarks for the updated Cherokee.

'We have a number of customers that have either defected or they've moved into something else because we didn't have a product offering for them. So, this is our chance to get them back into the family, and I think do some conquesting as well," Cox said.
2026-02-23 14:09 19d ago
2026-02-23 09:00 19d ago
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen stocknewsapi
LLY
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.

Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. 

The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug. Patients can use one pen to take four weekly doses of Zepbound. 

Currently, patients on the treatment use a different single-dose autoinjector device each week. Lilly also offers single-dose vials of Zepbound, which requires users to draw the medication into a syringe and inject themselves. 

The announcement comes as Lilly works to sustain the early success of Zepbound, which has exploded in demand since it first entered the market in late 2023. LillyDirect has been key to Zepbound's growth, and rolling out a new form of the drug on the platform could attract even more patients. 

The torrid growth of Zepbound has helped Eli Lilly seize a majority share of the weight-loss drug market from rival Novo Nordisk. In the company's fourth quarter, Zepbound brought in $4.2 billion in U.S. revenue, a 122% spike from the previous year.

In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device.

The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro. 

"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines," said Ilya Yuffa, the president of Lilly USA and Global Customer Capabilities, in the release. 
2026-02-23 14:09 19d ago
2026-02-23 09:00 19d ago
CoreWeave May Be Set For A High-Stakes Q4 Breakout (Preview) stocknewsapi
CRWV
CoreWeave, Inc. is upgraded from Hold to Buy ahead of Q4 earnings, citing improved execution and near-term catalysts. CRWV has diversified infrastructure partners, launched CoreWeave ARENA, and narrowed its software gap with peers, reducing execution risks. Backlog strength, early deployment of Nvidia's Rubin architecture, and a multi-billion dollar pipeline support medium-term earnings growth.
2026-02-23 14:09 19d ago
2026-02-23 09:01 19d ago
Consolidated Water to Attend the 38th Annual ROTH Conference, March 22-24, 2026 stocknewsapi
CWCO
GEORGE TOWN, Cayman Islands, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, has been invited to attend the 38th Annual ROTH Conference being held at The Ritz-Carlton Laguna Niguel in Dana Point, California, on March 22-24, 2026.

The conference will feature on-demand presentations by companies across a range of industry sectors, in-person one-on-one and small group meetings, industry panels, and fireside chats.

Past conferences have attracted more than 5,000 participants, comprised of institutional investors, family offices, high-net-worth investors, and equity analysts.

On March 23-24, Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with analysts and investors. He will be joined by the company’s CFO, David Sasnett, and its COO, Ramjeet Jerrybandan.

They will discuss the company’s operating results and growth drivers across its four business segments, including its Cayman Islands water utility company, Caribbean-based seawater desalination plants, and U.S.-based manufacturing and services businesses.

The company increased its quarterly cash dividend 27.3% to $0.14 per share beginning in the third quarter of 2025.

Submit your conference registration request here. To schedule a one-on-one meeting with Consolidated Water, please contact your ROTH representative.

For questions or further information about Consolidated Water, contact Ron Both of Encore IR at (949) 432-7557, or submit your request here.

About ROTH
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Its full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

About Consolidated Water Co. Ltd.
Consolidated Water Co. Ltd. develops and operates advanced water treatment plants and water distribution systems. The company designs, constructs and operates seawater desalination facilities in the Cayman Islands, The Bahamas and the British Virgin Islands, and designs, constructs and operates water treatment and reuse facilities in the United States.

The company also manufactures and services a wide range of products and provides design, engineering, management, operating and other services applicable to commercial and municipal water production, supply and treatment, and industrial water and wastewater treatment.

For more information, visit cwco.com.

Company Contact:
David W. Sasnett
Executive Vice President and CFO
Tel (954) 509-8200
Email Contact

Investor Relations Contact:
Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7557
Email Contact

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e65745c3-f405-4bd8-aaee-94621c45453c
2026-02-23 14:09 19d ago
2026-02-23 09:01 19d ago
Best-Performing ETFs of Last Week stocknewsapi
BWET
Wall Street was upbeat last week, withthe State Street SPDR S&P 500 ETF Trust (SPY - Free Report) adding about 1.1%, SPDR Dow Jones Industrial Average ETF Trust (DIA - Free Report) advancing 0.5%, Invesco QQQ Trust, Series 1 (QQQ - Free Report) gaining 1.4% and iShares Russell 2000 ETF (IWM - Free Report) tacking on 1.5% gains.

Last week was marked by heightened geopolitical tensions between the United States and Iran, which impacted oil and gas market heavily. Hence, the most notable gain was realized by oil ETFs. United States Oil Fund LP (USO - Free Report) and United States Brent Oil Fund LP (BNO - Free Report) rose 6.2% and 6.6% last week, respectively.

Rising Geopolitical Tensions Add Oil Supply ConcernsU.S. envoys Steve Witkoff and Jared Kushner held talks with Iranian officials in Geneva. However, U.S. Vice President JD Vance said Iran failed to meet key American demands during recent nuclear negotiations and warned that military action remains an option if diplomacy breaks down, as mentioned in a CNBC article. 

Meanwhile, Iran conducted military exercises in the Strait of Hormuz — a critical route for global energy shipments — raising fears that oil flows could be disrupted in the event of conflict.

Note that about one-third of all waterborne crude exports pass through this narrow waterway, according to data from energy consulting firm Kpler, as quoted on CNBC. The United States has also has strengthened its military presence in the Middle East by deploying aircraft carriers.

Supreme Court Rejects Emergency-law TariffsThe U.S. Supreme Court struck down sweeping tariffs imposed by Donald Trump under a national emergency law. In a 6–3 decision written by Chief Justice John Roberts, the court agreed with a lower court that the Republican president had surpassed his authority in using the 1977 law, per Reuters.

Lower-Than-Expected U.S. Growth RateThe U.S. economy expanded at an annualized 1.4% in Q4 2025, the least since Q1 2025, following a 4.4% advancement in Q3 and well below forecasts of 3%, as mentioned in Trading Economics. Consumer spending slowed (2.4% versus 3.5%). Analysts attributed the decline to the government shutdown, per the above-mentioned Reuters article.

Key Earnings of the WeekDeere (DE - Free Report) beat earnings estimates and raised its FY2026 outlook, sending the stock sharply higher on Feb. 19, 2026. Strong shipment volumes and demand recovery lifted Deere despite tariff concerns (read: Deere Stock Surges on Upbeat Earnings & Guidance: Agri ETFs to Play).

Shares of Walmart Inc. (WMT - Free Report) suffered, despite the company’s better-than-expected fourth-quarter fiscal 2026 results. Although it comfortably surpassed analysts’ estimates for earnings and revenues, the retail giant’s stock tumbled on the bourses, most likely owing to its earnings outlook for fiscal 2027, which fell short of Wall Street’s expectations (read: ETFs to Watch as Walmart Shares Slip Despite Q4 Earnings Beat). 

Against this backdrop, below we highlight the winning exchange-traded funds (ETFs) of the last week.

ETFs in FocusBreakwave Tanker Shipping ETF (BWET - Free Report) – Up 33.3% Last Week

The fund offers exposure to crude oil tanker shipping. Global shipping stocks rose due to sharply increased freight rates caused by ongoing disruptions in major trade routes – particularly the Red Sea – which force vessels to take longer journeys.

The Sprott Physical Silver Trust (PSLV - Free Report) – Up 8.9%

The dollar declined on Friday after the U.S. Supreme Court struck down President Donald Trump's sweeping tariffs based on a national emergency law, as quoted by Reuters. This boosted metal prices and materially supported silver prices.

Sprott Junior Uranium Miners ETF (URNJ - Free Report) – Up 8.0%

Uranium mining companies are experiencing upward momentum in early 2026, thanks to a tight supply-demand balance. There is an increasing demand from the utilities sector.

REX Drone ETF (DRNZ - Free Report) – Up 8.3%

Drone stocks are in favor due to the high demand for military and commercial applications, rapid technological advancements, and strong government backing for domestic manufacturing. 
2026-02-23 14:09 19d ago
2026-02-23 09:01 19d ago
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks stocknewsapi
IPGP PAHC RVLV SIMO
Key Takeaways Earnings surprises matter as stocks often drop if results miss or merely match expectations.A screen using EPS surprise history, growth outlook and rankings helps spot likely beaters.Likely winners: Revolve Group, Phibro Animal Health Corporation, Silicon Motion Technology and IPG Photonics. It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature.

In this regard, we ran a screener that yielded stocks Revolve Group (RVLV - Free Report) , Phibro Animal Health (PAHC - Free Report) , Silicon Motion Technology (SIMO - Free Report) and IPG Photonics (IPGP - Free Report) as the likely winners on the earnings beat potential.

Why Is a Positive Earnings Surprise So Important?Historically, stocks of companies with solid quarterly earnings (on a nominal basis) tank if they miss or merely meet market expectations. After all, a 20% earnings rise (though apparently looks good) doesn’t tell you if earnings growth has been exhibiting a decelerating trend.

Also, seasonal fluctuations come into play sometimes. If a company’s Q1 is seasonally weak and Q4 strong, then it is likely to report a sequential earnings decline. In such cases, growth rates are misleading when judging the true health of a company.

On the other hand, after much brainstorming and analysis of companies’ financials and initiatives, Wall Street analysts project earnings of companies. They, in fact, club their insights and a company’s guidance when deriving an earnings estimate.

Thus, outperforming that estimate is almost equivalent to beating the company’s own expectation as well as the market perception. And if the margin of earnings surprise is big, it typically drives the stock higher right after the release. Thus, more than anything else, an earnings surprise can push a stock higher.

How to Find Stocks That Can Beat?Now, finding stocks that have the potential to beat on the bottom line may be investors’ dream, but not an easy job. One way to do this is to look at the earnings surprise history of the company.

An impressive track in this regard generally acts as a catalyst in sending a stock higher. It indicates the company’s ability to surpass estimates. And investors generally believe that the company will apply the same secret sauce to execute yet another earnings beat in its next release.

The Winning StrategyIn order to shortlist stocks that are likely to come up with an earnings surprise, we chose the following as our primary screening parameters.

Last EPS Surprise greater than or equal to 10%: Stocks delivering positive surprise in the last quarter tend to surprise again.

Average EPS Surprise in the last four quarters greater than 20%: We lifted the bar for outperformance slight higher by setting the average earnings surprise for the last four quarters at 20%.

Average EPS Surprise in the last two quarters greater than 20%: This points to a more consistent surprise history and makes the case for another surprise even stronger.

In addition, we place a few other criteria that push up the chance of a positive surprise.

Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) rating can get through.

Earnings ESP greater than zero: A stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for an earnings beat to happen, as per our proven model.

In order to zero in on those that have long-term growth potential and high trading liquidity we have added the following parameters too:

Next 3–5 Years Estimated EPS Growth (Per Year) greater than 10%: Solid expected earnings growth exhibits the stock’s long-term growth prospects.

Average 20-day Volume greater than 100,000: High trading volume implies that the stocks have adequate liquidity.

A handful of criteria has narrowed down the universe from over 7,700 stocks to only four.

Here are all four stocks:

Revolve Group: The Zacks Rank #2 e-commerce fashion company markets and sells men's and women's designer apparel, shoes and accessories. You can see the complete list of today’s Zacks #1 Rank stocks here.

The average earnings surprise of RVLV for the past four quarters is 61.71%.

Phibro Animal Health: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. PAHC sports a Zacks Rank #1.

The average earnings surprise of PAHC for the past four quarters is 20.15%.

Silicon Motion Technology: The Zacks Rank #1 company is a leading developer of microcontroller ICs for NAND flash storage devices.

The average earnings surprise of SIMO for the past four quarters is 23.43%.

IPG Photonics: Oxford, MA-based IPG Photonics Corp develops and manufactures high-performance fiber lasers, fiber amplifiers and diode lasers that are used for diverse applications, including materials processing, medical and advanced applications. The stock has a Zacks Rank #1.

The average earnings surprise of IPGP for the past four quarters is 112.59%.
2026-02-23 14:09 19d ago
2026-02-23 09:01 19d ago
General Motors or Ford: Which Auto Biggie is a Better Buy Now? stocknewsapi
F GM
As EV sales slow and tariffs loom, read on to know why F may just have the edge over GM now.
2026-02-23 14:09 19d ago
2026-02-23 09:02 19d ago
Exclusive: ASML unveils EUV light source advance that could yield 50% more chips by 2030 stocknewsapi
ASML
SummaryCompaniesASML says EUV light boost to enable 50% more chips by 2030Power boost to 1,000W cuts chip costs, improves wafer outputUnited States, China aim to rival ASML amid export control talksSAN DIEGO, California, Feb 23 (Reuters) - Researchers at ASML Holding say they have found a way to boost the power of the light source in a key chip making machine to turn out up to 50% more chips by decade's end, to help retain the Dutch company's edge over emerging U.S. and Chinese rivals.

ASML (ASML.AS), opens new tab is the world's only maker of commercial extreme ultraviolet lithography (EUV) machines, a critical tool for chipmakers such as Taiwan Semiconductor Manufacturing Co, Intel and others in producing advanced computing chips.

The Reuters Inside Track newsletter is your essential guide to the biggest events in global sport. Sign up here.

"It's not a parlor trick or something like this, where we demonstrate for a very short time that it can work," Michael Purvis, ASML's lead technologist for its EUV source light, said in an interview.

"It's a system that can produce 1,000 watts under all the same requirements that you could see at a customer," he added, speaking at the company's California facilities near San Diego.

MACHINES CRITICAL TO CHIP PRODUCTIONThe EUV machines are so critical to chip production that U.S. governments of both parties have worked with Dutch leaders to prevent them from being shipped to China, spurring it to launch a national effort to build machines of its own.

In the United States, at least two startups, Substrate and xLight, have raised hundreds of millions of dollars to develop American competitors to ASML's technology, with xLight securing government funding from President Donald Trump's administration.

With the technological advance revealed on Monday, which is being reported here for the first time, ASML aims to outdistance any would-be rivals by improving the most technologically challenging aspect of the machines.

This is the quest to generate EUV light with the right power and properties to turn out chips at high volume. The company's researchers have found a way to boost the power of the EUV light source to 1,000 watts from 600 watts now.

The chief advantage is that greater power translates into the ability to make more chips every hour, helping to lower the cost of each.

Chips are printed similar to a photograph, where the EUV light is shone on a silicon wafer coated with special chemicals called a photoresist. With a more powerful EUV light source, chip factories need shorter exposure times.

"We'd like to make sure that our customers can keep on using EUV at a much lower cost," Teun van Gogh, executive vice president for the NXE line of EUV machines at ASML, told Reuters.

MACHINES COULD PROCESS 330 WAFERS AN HOUR BY 2030Van Gogh said customers should be able to process about 330 silicon wafers an hour on each machine by the end of the decade, up from 220 now. Depending on the size of a chip, each wafer can hold anywhere from scores to thousands of the devices.

ASML got the power boost by doubling down on an approach that already places its machines among the most complex inventions of humans.

To produce light with a wavelength of 13.5 nanometers, ASML's machine shoots a stream of molten droplets of tin through a chamber, where a massive carbon dioxide laser heats them into plasma.

This is a superheated state of matter in which the tin droplets become hotter than the sun and emit EUV light, to be collected by precision optic equipment supplied by Germany's Carl Zeiss AG and fed into the machine to print chips.

The key advancements in Monday's disclosure involved doubling the number of tin drops to about 100,000 every second, and shaping them into plasma using two smaller laser bursts, as opposed to today's machines that use a single shaping burst.

"It's very challenging, because you need to master many things, many technologies," said Jorge J. Rocca, a professor at Colorado State University whose lab focuses on laser technologies and has trained several ASML scientists.

"What was achieved - one kilowatt - is pretty amazing."

ASML believes the techniques it used to hit 1,000 watts will unlock continued advances in the future, Purvis said, adding, "We see a reasonably clear path toward 1,500 watts, and no fundamental reason why we couldn't get to 2,000 watts."

Reporting by Stephen Nellis in San Diego; Editing by Clarence Fernandez

Our Standards: The Thomson Reuters Trust Principles., opens new tab
2026-02-23 14:09 19d ago
2026-02-23 09:05 19d ago
Jeffs' Brands Sells 6.3% of Fort Technology's Outstanding Shares ; Company to Retain Majority Stake Valued at Approximately $24 Million Valuation stocknewsapi
JFBR
As part of its strategic shift, Company is divesting retail assets to focus on homeland security and advanced technologies

Tel Aviv, Israel, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced the closing of a share transfer agreement dated December 18, 2025 with institutional investors,  to sell and transfer 714,286 common shares of Fort Technology Inc. (TSXV: FORT) (“Fort”), for a total consideration of CAD $928,571 (approximately CAD $1.3 per share). The shares represent approximately 8.1% of Jeffs’ Brands holdings in Fort and approximately 6.3% of Fort’s outstanding shares.

Following the closing, the Company currently holds a 71.55% equity stake in Fort.

This transaction represents a partial divestment of the Company’s holdings in its majority-owned subsidiary and is expected to provide additional liquidity as the Company continues to execute its strategy to focus on homeland security and advanced technologies.

About Jeffs’ Brands

Jeffs’ Brands is a data-driven company that has recently pivoted into the global homeland security sector through its wholly-owned subsidiary, KeepZone AI Inc., following the entry into the definitive distribution agreement with Scanary Ltd., in December 2025. Jeffs’ Brands aims to deliver comprehensive, multi-layered security ecosystems for critical infrastructure worldwide, capitalizing on the homeland security market’s significant growth potential while leveraging its expertise in data-driven operations.

For more information on Jeffs’ Brands visit https://jeffsbrands.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when discussing the expected benefits of the partial divestment, the anticipated provision of additional liquidity, and the Company’s strategy and future focus on homeland security and advanced technologies.. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to adapt to significant future alterations in Amazon’s policies; the Company’s ability to sell its existing products and grow the Company’s brands and product offerings; the Company’s ability to meet its expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of the conditions in Israel; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (“SEC”), on March 31, 2025, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:

Michal Efraty
Adi and Michal PR- IR
Investor Relations, Israel
[email protected]
2026-02-23 14:09 19d ago
2026-02-23 09:06 19d ago
DEADLINE NEXT WEEK: Berger Montague Advises Fermi Inc. (NASDAQ: FRMI) Investors to Contact the Firm Before March 6, 2026 stocknewsapi
FRMI
PHILADELPHIA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI) (“Fermi” or the “Company”) on behalf of investors who purchased or otherwise acquired Fermi securities during the period of October 1, 2025 through December 11, 2025 (the “Class Period”), including in the Company’s initial public offering on October 1, 2025.

Investor Deadline: Investors who purchased Fermi securities during the Class Period may, no later than March 6, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Headquartered in Amarillo, Texas, Fermi plans to create a network of large, grid-independent data centers powered by nuclear, natural gas, solar, and battery energy.

The lawsuit alleges that during the Class Period, defendants misled investors regarding tenant demand for the Company’s Project Matador AI campus and the status of funding for that project.

The complaint further alleges that defendants concealed that Project Matador’s construction financing was dependent on a single tenant’s funding commitment and that there was a significant risk the tenant could withdraw its support. As a result, defendants’ public statements allegedly lacked a reasonable basis.

If you are a Fermi investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
[email protected]
2026-02-23 14:09 19d ago
2026-02-23 09:06 19d ago
Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus stocknewsapi
CL GTY NTLA
Key Takeaways Intellia Therapeutics has surged 57.2% in 12 weeks, outperforming the S&P 500's 5.6% rise.Getty Realty jumped 14.5% since Dec. 24 after being upgraded to a Zacks Rank #2.Colgate-Palmolive gained 20.6% in 12 weeks as part of the ECAP portfolio. Last Friday, the three most widely followed benchmark indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average advanced 1.5%, 1.1% and 0.3%, respectively.

The rally was driven by improving investor sentiment following a volatile start to the month, with growth stocks spearheading the recovery. Gains in technology and communication services stocks played a pivotal role, propelling the Nasdaq to the strongest performance among the three. Better-than-anticipated earnings from major corporations reinforced confidence in companies’ ability to sustain profits despite higher borrowing costs. Enthusiasm surrounding artificial intelligence investments and resilient consumer spending further bolstered risk-taking.

At the same time, moderating inflation data and steady Treasury yields reduced fears of additional aggressive rate hikes by the Federal Reserve. Market participants viewed recent economic indicators as evidence of a steady yet gradually cooling economy, prompting broad-based buying and enabling the key indexes to finish the week on a positive note.

Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market. 

As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.

Here are some of our key achievements:

Intrepid Potash and Getty Realty Surge Following Zacks Rank UpgradeShares of Intrepid Potash, Inc. (IPI - Free Report) have gained 17.7% (versus the S&P 500’s 0.2% increase) since it was upgraded to a Zacks Rank #2 (Buy) on Dec. 24.

Another stock, Getty Realty Corp.  (GTY - Free Report) , which was also upgraded to a Zacks Rank #2 on Dec. 24, has returned 14.5% since then.

An equal-weight portfolio of Zacks Rank # 1 (Strong Buy) stocks outperformed the equal-weight S&P 500 index by 7 percentage points (+17.81% for the Zacks Rank #1 stocks vs. +10.85% for the index).

This hypothetical equal-weight portfolio returned +22.4% in 2024 vs. +13.7% for the equal-weight S&P 500 index. Over the preceding 10-year period (2016 through 2025), this portfolio of qual-weight Zacks Rank #1 stocks has outperformed the equal-weight S&P 500 index by more than 7 percentage points (+18.55% vs. +11.65%).

You can see the complete list of today’s Zacks Rank #1 stocks here >>>

Check Intrepid’s historical EPS and Sales here>>>

Check Getty’s historical EPS and Sales here>>>

Image Source: Zacks Investment Research

Zacks Recommendation Upgrades Analog Devices and Sibanye StillwaterShares of Analog Devices, Inc. (ADI - Free Report) and Sibanye Stillwater Limited (SBSW - Free Report) have surged 30.9% and 11.9% (versus the S&P 500’s 1.1% rise), respectively, since their Zacks Recommendation was upgraded to Outperform on Jan. 1.

While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.

The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.

To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>

Zacks Focus List Stocks Intellia, Huntington Ingalls Shoot UpShares of Intellia Therapeutics, Inc. (NTLA - Free Report) , which belongs to the Zacks Focus List, have gained 57.2% over the past 12 weeks. The stock was added to the Focus List on March 7, 2023. Another Focus-List holding, Huntington Ingalls Industries, Inc. (HII - Free Report) , which was added to the portfolio on May 9, 2016, has returned 45% over the past 12 weeks. The S&P 500 has inched up 5.6% over this period. 

The 50-stock Focus List portfolio returned +5.22% in January 2026 vs. +1.45% for the S&P 500 index and +3.39% for the equal-weight version of the index.

The portfolio returned +22.1% in 2025 vs. +17.9% for the S&P 500 index and +11.4% for the equal-weight version of the index.

The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.

Through January 31st, 2026, the portfolio’s rolling one-year, three-years, five-years, ten-years and since 2004 has been +22.2% (vs. +16.35% for the S&P 500 index), +21.55% (vs. +21.12%), +15.13% (vs. +14.99%), +16.59% (vs. +15.57%) and +12.36% vs. (+10.74%), respectively.

Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>

Zacks ECAP Stocks Hershey’s & Colgate-Palmolive Gain SignificantlyThe Hershey Company (HSY - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 21.4% over the past 12 weeks. Colgate-Palmolive Company (CL - Free Report) followed Hershey with 20.6% returns.

The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned -2.3% in the fourth quarter of 2025 vs. the S&P 500 index’s +2.7% gain (SPY ETF). For 2025 as a whole, the portfolio returned -1.67% vs. +17.9% gain for the S&P 500 index.

For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).

In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.

With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.

The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.

Zacks ECDP Stocks Clorox and Illinois Tool Works Outperform PeersThe Clorox Company (CLX - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 23.5% over the past 12 weeks. Another ECDP stock, Illinois Tool Works Inc. (ITW - Free Report) , has climbed 22.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.

Check Clorox’s dividend history here>>>

Check Illinois Tool Works’ dividend history here>>>

With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk

The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -2.1% in 2025 Q4 vs. the S&P 500 index’s +2.7% gain and the Dividend Aristocrats ETF’s (NOBL) +1.6% return. For 2025, the portfolio returned -0.6% vs. +6.8% gain for the Dividend Aristocrat ETF.

For the full year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.

The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.

Click here to access this portfolio on Zacks Advisor Tools.  

Zacks Top 10 Stock Monolithic Power Delivers Solid ReturnsMonolithic Power Systems (MPWR - Free Report) , from the Zacks Top 10 Stocks for 2025, has jumped 28.6% since Jan. 5, 2026, compared with the S&P 500 Index’s 0.9% increase.

The Top 10 portfolio retuned +4.88% in January 2026 vs. +1.45% for the S&P 500 index and +3.39% for the equal-weight version of the index.

The Top 10 portfolio returned +22.6% in 2025 vs. +17.9% for the S&P 500 index and +11.4% for the equal-weight version of the index.

The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.

Through the end of January 2026, the Top 10 portfolio has produced a cumulative return of +2,616.9% since 2012 vs. +578.2% for the S&P 500 index and +416.7% for the equal-weight version of the index. The portfolio has produced an average annual return of +26.4% in the period 2012 through January 31st, 2026 vs. +14.8% for the S&P 500 index and +12.4% for the equal-weight version of the index.
2026-02-23 14:09 19d ago
2026-02-23 09:06 19d ago
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection stocknewsapi
GRAL
Another T206 Honus Wagner baseball card, considered to be the "Holy Grail" of the collectible space, was recently discovered and has been sold at auction for $5.124 million.

The sale was conducted via Goldin Auctions, and it included the buyer’s premium. It’s now the third-most expensive T206 Wagner card ever after a $6.606 million copy was sold in August 2021 and another for $7.25 million in August 2022. 

This recently discovered copy had been in the family of Douglas and Dennis Shields for 116 yards. Their grandfather, Morton Bernstein, the son of The National Silver Company founder, Samuel E. Bernstein, collected trading cards, and more importantly, preserved them since the early 1900s. 

CLICK HERE FOR MORE SPORTS COVERAGE ON FOXBUSINESS.COM

A rare baseball card of Honus Wagner of the Pittsburgh Pirates, considered to be the best all around player in baseball history, is displayed at a preview of a sports memorabilia sale on June 3, 2005, at Sotheby's in New York.  (STAN HONDA/AFP / Getty Images)

"We are honored that the Shields family chose us to represent this historic card that has been in their family for 116 years," Ken Goldin, CEO and found of Goldin Auctions said in a statement, via ESPN. 

This recently discovered copy was graded as a 1 by Professional Sports Authenticator (PSA), while the other two received grades of 3 and 2 respectively from Sportscard Guaranty Corporation (SGC) when they came about.  

LOGAN PAUL SELLS PIKACHU ILLUSTRATOR TRADING CARD FOR MORE THAN $16.4M

Morton Bernstein ended up purchasing F.B. Rogers Silver Company in 1955, and he made it a point to display his preserved cards in frames throughout his business. Ultimately, The National Silver Company went out of business, and the cards were placed in a warehouse. 

As Douglas and Dennis came forward, the T206 Wagner card was featured on Netflix’s "King of Collectibles: The Goldin Touch," where Goldin revealed it on a Season 3 episode in December. 

The famous T206 Honus Wagner baseball card, is shown June 6, 2000 in New York City. The legendary baseball card will be auctioned on eBay beginning on July 5, 2000. (Chris Hondros/Newsmakers / Getty Images)

While this is a massive payout for yet another Wagner card, another T206 remains on the market. With six days left on Heritage Auction, an SGC Authentic, which is considered a grade below a 1, is at $2.318 million right now. 

So, what exactly makes this card worth millions today? Scarcity in the collectibles industry is a major key, and since Wagner asked the American Tobacco Company to stop making his card in 1909, there is certainly that factor here. 

The 1909 baseball card of Pittsburgh Pirates shortstop Honus Wagner is displayed for a photograph in New York, U.S., on Tuesday, Feb. 19, 2013.  (Scott Eells/Bloomberg / Getty Images)

GET FOX BUSINESS ON THE GO BY CLICKING HERE

That was the same year Wagner won the World Series with the Pittsburgh Pirates, who he won eight batting titles with. Nicknamed ‘The Flying Dutchman," Wagner is one of the most recognized baseball players of all time, being amongst the original Hall of Fame inductees when the National Baseball Hall of Fame and Museum in Cooperstown, New York was founded. 

Follow Fox News Digital’s sports coverage on X and subscribe to the Fox News Sports Huddle newsletter.
2026-02-23 14:09 19d ago
2026-02-23 09:08 19d ago
TNR Gold NSR Royalty Update - Ganfeng's Mariana Lithium Completed the First Export of Lithium Chloride stocknewsapi
TRRXF
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - TNR Gold Corp. (TSXV: TNR) ("TNR", "TNR Gold" or the "Company") is pleased to announce that Litio Minera Argentina S.A., a subsidiary of Ganfeng Lithium ("Ganfeng Lithium") has provided an update on the Mariana Lithium Project in Argentina.
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Immunome to Present at Upcoming Investor Conferences stocknewsapi
IMNM
-

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management will present at the following investor conferences:

TD Cowen 46th Annual Health Care Conference

Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET

Leerink Partners Global Healthcare Conference

Presentation Date/Time: March 10, 2026, at 3 p.m. ET

Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.immunome.com. Replay webcasts will be available for approximately 30 days following the live presentations.

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage gamma secretase inhibitor; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.

More News From Immunome, Inc.

Back to Newsroom
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Atara Biotherapeutics Provides a Business Update stocknewsapi
ATRA
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty (“HCRx”). Under the terms of the Amendme.
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
The Federal Circuit Affirms PTAB Ruling Upholding Validity of Netlist '314 Patent stocknewsapi
NLST
IRVINE, CA / ACCESS Newswire / February 23, 2026 / Netlist, Inc. (OTCQB:NLST) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the October 2023 final written decision by the Patent Trial and Appeal Board (PTAB) upholding the validity of Netlist's U.S. Patent No. 10,489,314 (the '314 Patent) in an Inter Partes Review (IPR) brought by Micron. Micron has 90 days from the CAFC's judgment to file a petition to the U.S. Supreme Court.

C.K. Hong, Netlist's Chief Executive Officer, said: "We are pleased that the CAFC affirmed the validity of the '314 Patent. This is the third time within the past 12 months that the CAFC has affirmed the validity of Netlist patents asserted against Micron and/or Samsung. These affirmances of the validity of Netlist's patented technologies attest to Netlist's role as an innovation leader in the semiconductor memory industry."

In 2025, the CAFC affirmed the validity of Netlist's U.S. Patent Nos. 10,268, 608 (the '608 Patent) and 10,217,523 (the '523 Patent), which had been unsuccessfully challenged by both Micron and Samsung before the PTAB. The '314 and '608 Patents are asserted in Netlist's case against Micron in the U.S. District Court for the Western District of Texas (WDTX), which is currently stayed. Netlist U.S. Patent No. 9,824,035 is also asserted against Micron in the WDTX. The PTAB previously found that claims 2 and 6 of the '035 Patent were not invalid. Micron did not appeal that finding.

The '608 and '523 Patents are two of the six patents Netlist has asserted in its complaint before the U.S. International Trade Commission (ITC) against Samsung, Google and Super Micro. At the ITC, Netlist is seeking exclusion and cease and desist orders, which would direct U.S. Customs and Border Protection to stop Samsung memory products that infringe Netlist's patents from entering the U.S.

About Netlist

Netlist is a leading innovator in advanced memory and storage solutions. With a rich portfolio of patented technologies, Netlist's inventions are foundational to the advancement of AI computing. To learn more about Netlist, please visit www.netlist.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release include, without limitation, statements about Netlist's ability to execute on its strategic initiatives, the results of pending litigations and Netlist's ability to successfully defend its intellectual property. Forward-looking statements are statements other than historical facts and often address future events or Netlist's future performance and reflect management's present expectations regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These risks, uncertainties and other factors include, among others: risks that Netlist will suffer adverse outcomes in its litigation with Samsung, Micron or Google or in its various other active proceedings to defend the validity of its patents; risks related to Netlist's plans for its intellectual property, including its strategies for monetizing, licensing, expanding, and defending its patent portfolio; risks associated with patent infringement litigation initiated by Netlist, or by others against Netlist, as well as the costs and unpredictability of any such litigation; the competitive landscape of Netlist's industry; and general economic, political and market conditions, including the ongoing conflicts between Russia and Ukraine and Israel and Palestine, factory slowdowns and/or shutdowns, and changes in international tariff policies. All forward-looking statements reflect management's present assumptions, expectations and beliefs regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These and other risks and uncertainties are described in Netlist's Annual Report on Form 10-K for the fiscal year ended December 28, 2024 filed with the SEC on March 28, 2025, and the other filings it makes with the U.S. Securities and Exchange Commission from time to time, including any subsequently filed quarterly and current reports. In particular, you are encouraged to review the Company's Quarterly Report on Form 10-Q for the quarter ended September 27, 2025 filed with the SEC on November 12, 2025. In light of these risks, uncertainties and other factors, these forward-looking statements should not be relied on as predictions of future events. These forward-looking statements represent Netlist's assumptions, expectations and beliefs only as of the date they are made, and except as required by law, Netlist undertakes no obligation to revise or update any forward-looking statements for any reason.

For more information, please contact:

Investors/Media
Mike Smargiassi
The Plunkett Group
[email protected]
(212) 739-6729

SOURCE: Netlist, Inc.
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
ALT5 Sigma Corporation Issues Stockholder Letter and Provides Corporate Update stocknewsapi
ALTS
Acting CEO Tony Isaac Outlines Compliance Restoration, Governance Strengthening, and Strategy to Drive Long-Term Stockholder Value

LAS VEGAS, NEVADA / ACCESS Newswire / February 23, 2026 / ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech company operating institutional-grade global payments, trading, and settlement infrastructure, today issued a letter to stockholders from Tony Isaac, Acting Chief Executive Officer.

Dear Stockholders,

Over the past 60 days, our focus has been clear: restore compliance, strengthen governance, sharpen operational discipline, and position ALT5 to better align its market valuation with its underlying asset base and infrastructure platform.

This update is intended to provide transparency regarding recent operational, compliance, and corporate developments, as well as to outline how we intend to execute with discipline and support sustainable long-term value creation.

Restoring Compliance and Strengthening the Foundation

During the past two months, we have made meaningful strides across several critical areas:

Returned to compliance with applicable U.S. Securities and Exchange Commission reporting requirements

Regained compliance with applicable Nasdaq listing requirements

Reorganized certain business operations to improve efficiency, internal controls, and oversight

Expanded and enhanced investor outreach and engagement initiatives

We have filed all required reports to restore timeliness under our SEC reporting obligations and are committed to maintaining full compliance with applicable filing deadlines going forward. In addition, the Company has regained compliance with applicable Nasdaq listing requirements. Strengthening financial controls, reporting discipline, and governance standards is foundational to restoring confidence and supporting long-term value creation.

In parallel, we have refined our operational structure to better align oversight, accountability, and execution across our payments, trading, and settlement infrastructure.

Governance and Leadership Updates

As previously disclosed in our Current Report on Form 8-K filed November 26, 2025:

The Board concluded Jonathan Hugh's employment as Chief Financial Officer and acting Chief Executive Officer, without cause, effective November 1, 2025.

Ron Pitters was provided notice on November 25, 2025 of the Board's decision to conclude his Consulting Agreement in accordance with its terms.

We remain engaged in constructive discussions to resolve any outstanding economic matters with these two individuals. These changes reflect our commitment to strengthening governance, oversight, and executive alignment as we execute our long-term strategy. Subsequent to these changes, the Company appointed Steven Plumb as Chief Financial Officer and added Dr. Adel Elmessiry and Tim Stanley to its Board of Directors, reinforcing financial oversight and governance alignment.

Rwanda Subsidiary Matter

As previously disclosed in our Current Report on Form 8-K filed August 29, 2025, and updated in our Quarterly Report filed January 12, 2026, on May 7, 2025, the Intermediate Court of Nyarugenge, Rwanda, rendered a judgment concerning our Canadian indirect, second-tier subsidiary and its former principal, related to approximately US$3.5 million held at I&M Bank in Rwanda.

The court ordered that the US$3.5 million be permanently forfeited to the Rwandan State Treasury. The judgment is currently on appeal before the High Court of Kigali, Rwanda.

In connection with the Intermediate Court's decision, we recorded a US$3.5 million allowance on our condensed consolidated balance sheets. As a result, there will be no additional financial statement impact should the appeal be unsuccessful. Conversely, if the appeal is successful, we would expect to recapture some or all of the allowance.

We continue to pursue all available remedies to protect the interests of the Company and its stakeholders.

Aligning Market Valuation with Intrinsic Value

As of February 19, 2026, ALT5's closing share price was $1.52, implying an equity market capitalization of approximately $192 million based on 126,339,124 outstanding shares of our common stock.

Based on management's recent estimate of net asset value (NAV) as of February 19, 2026, which includes digital asset holdings, cash, and all other assets, the Company's NAV is approximately $843 million, or $6.67 per issued and outstanding share of common stock, implying that ALT5 shares trade at approximately a 77% discount to intrinsic value.

Our objective is to reduce this valuation misalignment over time through disciplined execution, transparent communication, and thoughtful capital allocation.

As previously announced, our Board authorized a share repurchase program designed to allocate our capital opportunistically when management and the Board determine that market pricing does not accurately reflect the intrinsic value of our underlying net asset base and operating platform. When executed prudently and in accordance with applicable regulations, these repurchases will represent a direct mechanism to enhance per-share value and capital efficiency.

We remain focused on capital structure discipline, prudent management of dilution, and long-term stockholder alignment.

ALT5 has processed more than $8 billion in digital asset transactions since inception. Sustained operational performance, institutional adoption, and transaction scalability remain central to reinforcing the strength of our infrastructure platform.

In February 2026, we announced the launch of ALT5 Ai, a strategic business unit designed to extend our regulated payment and settlement infrastructure into Ai-driven commerce, and appointed Bill Inman as Chief Innovation Strategist and Spokesperson. In this role, Mr. Inman will guide the Company's intended expansion at the intersection of artificial intelligence, decentralized systems, and enterprise payment infrastructure.

As artificial intelligence systems increasingly execute workflows, authorize transactions, and interact across digital environments, we believe enterprise-grade payment rails capable of secure authorization, compliance oversight, and real-time settlement will become foundational infrastructure. ALT5 Ai is intended to build upon our existing operating platform by enabling Ai-to-enterprise and Ai-to-Ai transaction capabilities aligned with institutional compliance standards.

Recent mainstream financial media coverage has highlighted initiatives within the broader World Liberty Financial ecosystem, reflecting increasing visibility and evolving real-world utility across digital asset markets. As compliant digital asset infrastructure continues to mature and practical applications expand, we believe enterprise-grade platforms positioned at the intersection of payments and digital assets will increasingly reflect their underlying value in public markets.

Looking Ahead

With compliance restored, governance strengthened, and previously disclosed matters appropriately addressed in our financial statements, our focus remains on disciplined execution across our regulated payments and digital asset infrastructure.

We appreciate the continued engagement of our stockholders and look forward to providing further updates as we execute this next phase of the Company's development.

Sincerely,

Tony Isaac
Acting Chief Executive Officer
ALT5 Sigma Corporation

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA:5AR1) is a fintech company with a strategic $WLFI digital asset treasury strategy initiative and an established global payments, trading, and settlement infrastructure, including card-based programs supporting crypto-to-fiat and fiat-to-crypto transactions. Since the inception of the Company's processing platforms in 2018, the Company has leveraged its blockchain infrastructure expertise and proven track record of processing over $8 billion in cryptocurrency transactions to optimize its digital asset treasury operations and capitalize on growing $WLFI ecosystem developments across retail platforms, payment integrations, and international market expansion.

Forward-looking Statements

The referenced letter, including the section entitled "Looking Ahead", contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the growth of USD1, ALT5's ability to benefit from the growth of USD1, the value of ALT5's $WLFI holdings, ALT5's accelerated growth in digital asset treasury operations, the positioning of the Company in the digital asset treasury sector, and the profitability and prospective growth of ALT5's platforms and business that are subject to risks that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion, and statements regarding the Company's potential separation plans of its biotech business. Words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions may indicate forward-looking statements, though not all forward-looking statements contain such words. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, including international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in the referenced letter. Such factors could include, among others, changes in the value of $WLFI tokens, a downturn in the adoption of stable coins, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of the referenced letter and the date of this Current Report on Form 8-K and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Relations

ALT5 Sigma Corporation
Phone: +1 (888) 778-7091
Email: [email protected]

Investor Relations

Gateway Group, Inc.
Phone: +1 (949) 574-3860
Email: [email protected]

SOURCE: ALT5 Sigma Corp.
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Cardinal Energy Ltd. Announces 2025 Year-End Reserves stocknewsapi
CRLFF
Calgary, Alberta--(Newsfile Corp. - February 23, 2026) - Cardinal Energy Ltd. (TSX: CJ) ("Cardinal" or the "Company") is pleased to present the results of its independent reserve reports effective December 31, 2025. Consistent with prior years, Cardinal's year-end 2025 non-thermal reserves were evaluated by GLJ Ltd. ("GLJ"). The thermal reserves were independently evaluated by McDaniel & Associates Consultants Ltd. ("McDaniel") (the GLJ report and the McDaniel report being collectively the "2025 Reserve Report").

The 2025 financial information in this news release is unaudited and accordingly, such financial information is subject to change based on the results of the Company's year-end audit.

Cardinal's 2025 year-end reserves reflect the quality, predictability, and sustainability of our low decline conventional asset base which is now being supplemented and enhanced by the growing recognition of reserves and value from the Company's first operational thermal heavy oil development at Reford, Saskatchewan ("Reford 1").

Scott Ratushny, Cardinal's Chairman and CEO commented, "2025 was an exciting year of transition for Cardinal. The significant up-front facility investment for Reford 1 that was reflected in last year's reserve report is now behind us, and we can now look forward to decades of predictable free cash flow and low-cost reserve additions from this asset. We look forward to replicating this success as we now embark on Reford 2, a similar thermal project to Reford 1, which is expected to increase Cardinal's production by more than 15% in 2027."

RESERVE REPORT HIGHLIGHTS

All reserves information contained in this news release are based on the 2025 Reserve Report.

After growing its Total Proved plus Probable ("TPP") reserves by 30% at year-end 2024 with the addition of its first thermal project at Reford 1, the conversion of these bookings into higher value reserve categories continued in 2025. Cardinal's Total Proved ("TP") reserves increased by 24% (21% per basic share)(4) in 2025 at a Finding, Development, and Acquisition ("FD&A")(1)(2) cost of $21.77/boe;

Despite a modest capital budget being directed to our conventional assets in 2025, Cardinal delivered production replacement of 1.1x within the Proved Developed Producing ("PDP") reserve category. This was achieved through the addition of six producing SAGD well pairs at Reford and continued positive technical revisions from Cardinal's conventional assets that benefit from established enhanced oil recovery schemes for long-life reserves. Cardinal replaced 3.4x production in TP reserve category with 64% of Reford 1 reserves now classified as proved;

Reford 1 year-end 2025 reserve bookings grew to 5.8 million boe PDP, 25.7 million boe TP, and 40.1 million boe TPP, representing 7%/25%/27% of the total corporate reserves by category, respectively. The before tax net present value discounted at 10% ("NPV10") of Reford 1 is estimated at $507 million ($3.16 per basic share)(4) based on the three consultant's average (GLJ, McDaniel and Sproule Associates Ltd., collectively, the "Consultants") pricing forecast as at December 31, 2025;

Future thermal projects, including Reford 2 and Kelfield, remain unbooked at this time and were not captured in the Company's year-end 2025 Reserve Report. Cardinal's thermal upside has recently become more tangible with the Company formally sanctioning the Reford 2 project on January 28, 2026, alongside the concurrent $104.7 million equity financing. With this in place we are anticipating Cardinal will recognize another step-change in reserve additions for next year-end;

Cardinal's TPP reserves now consist of 93% light, medium and heavy crude oil and natural gas liquids ("NGL's") and 7% natural gas;

Notes:
(1) FD&A costs is a non-GAAP financial ratio. Development costs is a non-GAAP financial measure and is used as a component of the non-GAAP financial ratio. See "Oil and Gas Metrics" and "Non-GAAP and Other Financial Measures" in this news release for information relating to these non-GAAP financial ratios and measures.
(2) Company interest reserves were utilized in the calculation of FD&A costs. This included the consideration of royalty interest volumes produced of 11 mboe (2 mbbl of heavy crude oil; 8 mbbl of light and medium crude oil and 10 mmcf of natural gas).
(3) See also "Note Regarding Forward-Looking Statements", "Reserves Advisories" and "Reserve Definitions".
(4) At year-end 2025, there were 160,650,490 basic outstanding shares and 167,468,085 diluted shares outstanding.

CARDINAL'S TOP TIER RESERVE LIFE ASSETS

Cardinal continues to maintain a reserve life index ("RLI")(1) of 9.1 years PDP, 12.5 years TP, and 17.2 years TPP based on fourth quarter 2025 production. This reflects the low risk and predictable nature of our asset base that continues to demonstrate one of the lowest production decline rates amongst Cardinal's peers.

Cardinal's three-year average FD&A(1) costs for PDP, TP and TPP is $20.27/boe, $19.81 and $17.05/boe respectively.

The Company has multiple years of conventional inventory to be developed alongside the continued expansion of our thermal asset portfolio.

Notes:
(1) See "Oil and Gas Metrics".
(2) See also "Note Regarding Forward-Looking Statements", "Reserves Advisories" and "Reserve Definitions".

OIL AND GAS RESERVES

The 2025 Reserve Report was prepared in accordance with definitions, standards and procedures contained in the Canadian Oil and Gas Evaluation Handbook ("COGEH") and National Instrument 51-101 - Standards of Disclosure for Oil and Gas Activities ("NI 51-101"). Please also refer to "Note Regarding Forward-Looking Statements", "Reserves Advisories" and "Reserve Definitions" in this news release.

Our 2025 Reserve Report uses the price forecast of the Consultants outlined below.

Summary of Oil and Gas Reserves (1)(2)

The following tables summarize certain information contained in the 2025 Reserve Report. Reserves included below are the Company's estimated gross reserves as at December 31, 2025, as evaluated in the 2025 Reserve Report.

Reserves CategoryLight and Medium Oil (MMbbl)Heavy Crude Oil (MMbbl)Natural Gas Liquids (MMbbl)Conventional
Natural Gas(3) (Bcf)Total BOE (MMboe)Proved Developed Producing36.932.92.735.278.4Proved Developed Non-Producing0.80.40.14.42.0Proved Undeveloped4.721.00.35.626.9Total Proved42.454.33.145.2107.3Probable 14.023.20.913.440.3Total Proved Plus Probable56.477.54.058.6147.6Notes:
(1) Total values may not add due to rounding.
(2) In addition to the gross reserves indicated in the above table, the Company has 178 Mboe TPP royalty interest reserves
comprised of 142 Mbbl light and medium crude oil, 17 Mbbl of heavy crude oil, 2 Mbbl of natural gas liquids and 106 MMcf of conventional natural gas.
(3) Includes non-associated gas, associated gas and solution gas.

Summary of Net Present Values of Future Net Revenue (Before Tax) 
(Based on forecast price and costs)

As at December 31, 2025(1)(2)(3)

Discounted at:Reserves Category0.0%
(MM$)5.0%
(MM$)10.0%
(MM$)15.0%
(MM$)20.0%
(MM$)Proved Developed Producing2,1191,6171,2611,036886Proved Developed Non-Producing(4)(163)(80)(50)(35)(27)Proved Undeveloped621410282202150Total Proved2,5781,9471,4931,2031,008Probable 1,649820494336248Total Proved Plus Probable4,2272,7671,9871,5401,257Notes:
(1) Total values may not add due to rounding.
(2) Based on Three Consultant's average, as defined below, December 31, 2025 forecast prices and costs. See below for "Price Forecast".
(3) Future net revenue has been reduced for future abandonment costs and estimated capital for future development associated with the reserves.
(4) All abandonment, decommissioning and reclamation ("ADR") cost, including active (costs included in PDP category) and inactive (included in the Proved Developed Non-Producing ("PDNP") category). The NPV10 of PDNP excluding ADR would be $23.7 million.

Reconciliation of Changes in Reserves(1)

The following table sets out a reconciliation of the changes in the Company's gross reserves as at December 31, 2025 against such reserves at December 31, 2024 based on forecast prices and cost assumptions in effect at the applicable reserve evaluation date.

Total ProvedLight and Medium Crude Oil
(MMbbl)Heavy Crude Oil
(MMbbl)Conventional
Natural Gas
(Bcf)Natural Gas Liquids (MMbbl)MBOE
(MMboe)December 31, 202450.626.248.82.987.9Acquisitions & Divestitures-(0.2)(0.1)-(0.2)Discoveries-----Extensions and Infill Drilling0.126.3--26.1Technical Revisions (2)(4.4)6.02.40.52.5Economic Factors (3)(0.7)(0.4)(1.3)-(1.4)Production(3.2)(3.6)(4.7)(0.3)(8.0)December 31, 202542.454.345.23.0107.3Total Proved Plus ProbableLight and Medium Crude Oil
(MMbbl)Heavy Crude Oil
(MMbbl)Conventional
Natural Gas
(Bcf)Natural Gas Liquids (MMbbl)MBOE
(MMboe)December 31, 202467.072.763.53.8154.2Acquisitions & Divestitures(0.1)(0.2)(0.1)-(0.3)Discoveries-----Extensions and Infill Drilling0.22.4--2.3Technical Revisions (2)(6.4)6.81.70.51.1Economic Factors (3)(1.1)(0.6)(1.8)(0.1)(2.0)Production(3.2)(3.6)(4.7)(0.3)(8.0)December 31, 202556.477.558.63.9147.6Notes:
(1) Total values may not add due to rounding.
(2) Positive or negative revisions are due to variations in performance versus previous forecasts, including improved recovery revisions.
(3) Economic factors have been calculated as the difference in reserves using the 2025 Reserve Report price forecast with the 2024 reserve report price forecasts. There is no consideration of changes in operating costs or price offset changes that occurred in 2025.

Price Forecast

The following table summarizes Consultant's average commodity price forecast and foreign exchange rate assumptions as at December 31, 2025, as applied in the 2025 Reserve Report, for the next five years.

Consultants Average Price Forecast(1)Exchange RateWTI @ CushingCanadian Light Sweet 40° APIWestern Canada Select 20.9° APIMedium at Cromer 29° APINatural gas AECO - C spotYear($C/$US)($US/bbl)($C/bbl)$C/bbl)($C/bbl)($C/MMbtu)20260.72859.9277.5465.1275.603.0020270.73765.1083.6070.4381.513.3020280.74070.2890.1876.9087.923.4920290.74071.9392.3278.7190.013.5820300.74073.3794.1780.2991.823.65Note:
(1) Inflation is accounted for at nil for 2026, and 2% thereafter.

Future Development Costs

Cardinal has conservatively booked undeveloped locations, reflecting our current drilling plans for the next three to four years. Meaningful potential drilling inventory exists beyond those locations and the associated reserves currently booked. Thermal reserves are a reflection of our Reford 1 project only, with potential future reserve expansion and value of other identified thermal projects currently not recognized in the 2025 Reserve Report.

Future Development Costs ("FDC") reflects the best estimate of the capital costs required to produce the Company's reserves. The FDC associated with the TPP reserves at year-end 2025 is $710 million undiscounted ($329 million discounted at 10%).

millions $PDPTotal ProvedTotal Proved plus ProbableTotal FDC, Undiscounted71579710Total FDC, Discounted at 10%43330329FDC included at year-end 2025 for CO2 purchases, maintenance and facility capital in PDP, TP and TPP were $71 million, $73 million and $83 million, respectively. Cardinal's Reford 1 thermal project accounts for 69% ($488 million) of the inflated, undiscounted TPP FDC.

Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively "forward-looking information") within the meaning of applicable securities laws relating to the Cardinal's plans and other aspects of Cardinal's anticipated future operations, management focus, objectives, strategies, financial, operating and production results. Forward-looking information typically uses words such as "anticipate", "believe", "project", "expect", "goal", "plan", "intend", " may", "would", "could" or "will" or similar words suggesting future outcomes, events or performance. The forward-looking statements contained in this news release speak only as of the date thereof and are expressly qualified by this cautionary statement.

Specifically, this news release contains forward-looking statements relating to: our asset base and its future potential and opportunities; that we will receive decades of predictable free cash flow and low-cost reserve additions from Reford 2; that the Company's success at Reford 1 will be replicated at Reford 2; that Reford 2 will increase our production by more than 15% in 2027; that the Company has multiple years of conventional inventory to be developed alongside the continued expansion of our thermal assets; future development capital; the life of our reserves; the booking of undeveloped locations which reflect our current drilling plans; our views that significant potential drilling inventory exists beyond those currently booked; the potential for reserve expansion to other identified projects currently not recognized in the 2025 Reserve Report; and that Cardinal will recognize a step-change in TPP reserves at the end of 2026.

In addition, information and statements relating to reserves are deemed to be forward-looking statements, as they involve implied assessment, based on certain estimates and assumptions, that the reserves described exist in quantities predicted or estimated, and that the reserves can be profitably produced in the future.

Forward-looking statements regarding Cardinal are based on certain key expectations and assumptions of Cardinal concerning anticipated financial performance, business prospects, strategies, regulatory developments, current and future commodity prices and exchange rates, applicable royalty rates, tax laws, future well production rates and reserve volumes, future operating costs, inflation, the performance of existing and future wells, the success of its exploration and development activities, the development of current and other potential thermal properties, the sufficiency and timing of budgeted capital expenditures in carrying out planned activities, the availability and cost of labor and services, the impact of competition, conditions in general economic and financial markets, access to markets, availability of drilling and related equipment, effects of regulation by governmental agencies, the ability to obtain financing on acceptable terms which are subject to change based on commodity prices, market conditions and potential timing delays.

These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond Cardinal's control. Such risks and uncertainties include, without limitation: the impact of general economic conditions; volatility in market prices for crude oil and natural gas; industry conditions; currency fluctuations; imprecision of reserve estimates; liabilities inherent in crude oil and natural gas operations; environmental risks; incorrect assessments of the value of exploration and development programs; competition from other producers; the lack of availability of qualified personnel, drilling rigs or other services; changes in income tax laws or changes in royalty rates and incentive programs relating to the oil and gas industry; hazards such as fire, explosion, blowouts, and spills, each of which could result in substantial damage to wells, production facilities, other property and the environment or in personal injury; and ability to access sufficient capital from internal and external sources.

Management has included the forward-looking statements above and a summary of assumptions and risks related to forward-looking statements provided in this news release in order to provide readers with a more complete perspective on Cardinal's future operations and such information may not be appropriate for other purposes. Cardinal's actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits that Cardinal will derive therefrom. Readers are cautioned that the foregoing lists of factors are not exhaustive. These forward-looking statements are made as of the date of this news release and Cardinal disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Oil and Gas Metrics

The term "boe" or barrels of oil equivalent may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 Mcf: 1 bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Additionally, given that the value ratio based on the current price of crude oil, as compared to natural gas, is significantly different from the energy equivalency of 6:1; utilizing a conversion ratio of 6:1 may be misleading as an indication of value.

This news release contains metrics commonly used in the oil and natural gas industry which have been prepared by management, such as "development costs", "FD&A costs", "reserve life index" and "replacement rate". These terms do not have a standardized meaning and may not be comparable to similar measures presented by other companies, and therefore should not be used to make such comparisons.

"Development costs" means the aggregate exploration and development costs including land and seismic incurred in the financial year on reserves that are characterized as development but exclude capitalized general and administration costs. The aggregate of the development costs incurred in the most recent financial year and the change during that year in estimated future development costs generally will not reflect total finding and development costs related to reserves additions for that year. Costs associated with exploration and evaluation assets have been excluded from this calculation. See "Non-GAAP Financial Measures".

"FD&A costs" are calculated as the sum of development costs plus net acquisition costs plus the change in FDC for the period when appropriate, divided by the change in reserves within the applicable reserves category, inclusive of changes due to acquisitions and dispositions. Costs associated with exploration and evaluation assets have been excluded from this calculation.

"Reserve life index" or "RLI" is calculated by dividing the applicable reserves by 2025 fourth quarter production of 23,500 boe/d for the PDP and TP reserve categories.

"Replacement rate" or similar terms does not have a standardized meaning and may not be comparable to similar measures presented by other companies and, therefore, should not be used to make such comparisons. Replacement rate (and similar terms) is the amount added to the Company's applicable reserves, divided by production. It is a measure of the ability of the Company to sustain production levels.

Management uses these oil and gas metrics for its own performance measurements and to provide shareholders with measures to compare our operations over time. Readers are cautioned that the information provided by these metrics, or that can be derived from the metrics presented in this news release, should not be relied upon for investment or other purposes.

Unaudited Financial Information

Certain financial and operating information included in this news release for the year ended December 31, 2025 are based on estimated unaudited financial results for the year then ended, and are subject to the same limitations as discussed under "Note Regarding Forward-Looking Statements". These estimated amounts may change upon the completion of audited financial statements for the year ended December 31, 2025 and such changes could be material.

Supplemental Information Regarding Product Types

This news release includes references to 2025 fourth quarter production. The following table is intended to provide the product type composition as defined by NI 51-101.

Light/medium Crude OilHeavy OilNGLConventional Natural GasTotal (boe/d) Q4 202542%46%3%9%23,500Reserves Advisories

In the 2025 Reserve Report, Cardinal has included all ADR costs for active and inactive wells and facilities. The ADR costs for the active assets are considered in the PDP reserves category. Full inclusion of all ADR costs is recommended by COGEH. Cardinal's full inclusion of costs exceeds the NI 51-101 minimum requirement of ADR for only those assets assigned reserves.

Consistent with prior years and in accordance with COGEH recommendations, Cardinal has included all operating costs for active and inactive assets. The Company also includes the consideration of future maintenance costs which are included as part of the operating costs or as FDC.

Unless otherwise indicated, all reserves reported in this news release are Company share gross reserves which represent Cardinal's total working interest reserves prior to the deduction of royalties payable.

Future net revenue is a forecast of revenue, estimated using forecast prices and costs arising from the anticipated development and production of resources, net of associated royalties, operating costs, development costs and all corporate abandonment and reclamation costs for all active and inactive wells, pipelines and facilities. It should not be assumed that the future net revenues undiscounted and discounted at 10% included in this news release represent the fair market value of the reserves.

The estimates of reserves and future net revenue for individual properties may not reflect the same confidence level as estimates of reserves and future net revenue for all properties due to the effects of aggregation.

Reserve Definitions

"Proved" reserves are those reserves that can be estimated with a high degree of certainty to be recoverable. It is likely that the actual remaining quantities recovered will exceed the estimated proved reserves.

"Probable" reserves are those additional reserves that are less certain to be recovered than proved reserves. It is equally likely that the actual remaining quantities recovered will be greater or less than the sum of the estimated proved plus probable reserves.

"Developed" reserves are those reserves that are expected to be recovered from existing wells and installed facilities or, if facilities have not been installed, that would involve a low expenditure (e.g. when compared to the cost of drilling a well) to put the reserves on production.

"Developed Producing" reserves are those reserves that are expected to be recovered from completion intervals open at the time of the estimate. These reserves may be currently producing or, if shut-in, they must have previously been on production, and the date of resumption of production must be known with reasonable certainty.

"Developed Non-Producing" reserves are those reserves that either have not been on production, or have previously been on production, but are shut-in, and the date of resumption of production is unknown.

"Undeveloped" reserves are those reserves expected to be recovered from known accumulations where a significant expenditure (for example, when compared to the cost of drilling a well) is required to render them capable of production. They must fully meet the requirements of the reserve's classification (proved, probable, possible) to which they are assigned.

Non-GAAP and Other Financial Measures

Throughout this news release and in other materials disclosed by the Company, Cardinal employs certain measures to analyze its financial performance, financial position, and cash flow. These non-GAAP and other financial measures are not standardized financial measures under International Financial Reporting Standards ("IFRS" or, alternatively, "GAAP") and may not be comparable to similar financial measures disclosed by other issuers. The non-GAAP and other financial measures should not be considered to be more meaningful than generally accepted accounting principles ("GAAP") measures which are determined in accordance with IFRS, such as net earnings (loss) and cash flow from operating activities as indicators of Cardinal's performance.

Non-GAAP Financial Measures

"Development costs" means the aggregate property, property plant and equipment expenditures including land and seismic incurred in the financial year on reserves that are characterized as development but exclude capitalized general and administration costs.

Non-GAAP Financial Ratios

"FD&A costs" is a non-GAAP financial ratio. See "Oil and Gas Advisories". Management uses FD&A costs as a measure of capital efficiency for organic and acquired reserves development.

About Cardinal Energy Ltd.

Cardinal is a Canadian oil and natural gas production company with operations focused on low decline sustainable oil production in Western Canada. The Company's portfolio of conventional and SAGD projects offers a complimentary low decline, long life resource base that is ideally suited to sustain our commitment to meaningful dividend returns to shareholders.

For further information:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284802

Source: Cardinal Energy Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
After Strong Q4 Result, Five9 Looks Appealing For Contrarians stocknewsapi
FIVN
After Strong Q4 Result, Five9 Looks Appealing For Contrarians
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Telescope Innovations Installs Second Self-Driving Lab at Pfizer stocknewsapi
TELIF
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of enabling technologies and services for the global pharmaceutical and chemical industries, is pleased to announce the installation of its second Self-Driving Laboratory ("SDL") at Pfizer, as part of the multi-year agreement between the companies. The installation was completed in January 2026.

TRANSACTION HIGHLIGHTS

The present SDL installation marks a key milestone in the transition from collaborative R&D to potential full-scale deployment.

The SDL is designed to significantly reduce development timelines and generate cost savings; it is a leading-edge approach to chemistry research guided by artificial intelligence, informed by advanced process analytical technology, and executed by robotic automation.

ABOUT THE SELF-DRIVING LAB ("SDL")

The SDL is a fixed-position Physical AI platform that integrates collaborative robotics, real-time inline analytics (Process Analytical Technology, or PAT), and machine-learning-guided experimental design within a continuous, autonomous closed-loop workflow. The system sets up chemical reactions, measures kinetics in real time, and determines the next optimal experiment, all without researcher intervention, enabling 24/7 operation across multiple reaction vessels simultaneously. By dramatically increasing experimental throughput, the SDL accelerates the development of chemical synthesis methods by up to 100 times compared to traditional manual approaches.

MANAGEMENT COMMENTARY

Henry Dubina, CEO of Telescope Innovations, commented: "The installation of our second SDL at one of the world's largest pharmaceutical companies is a testament to the strength of our ongoing partnership with Pfizer. Beyond the potentially significant cost savings during drug development, the SDL aims to compress the development cycles which could enable the acceleration of new innovations into the market."

Dr. Jason Hein, Founder and CTO, added: "With this second SDL deployment, we are pleased to continue demonstrating Physical AI at work, moving beyond digital models into the real world of chemistry, where the platform generates novel insights that could not be obtained through simulation alone. The core closed-loop architecture is directly transferable to any domain that requires rapid optimization of chemical or materials processes, from pharmaceutical innovation to advanced manufacturing and beyond."

About Telescope Innovations

Telescope Innovations Corp. is a developer of intelligent automation and advanced chemical manufacturing technologies. The Company builds and deploys enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. The Company's "Self-Driving Labs" are fully autonomous, physical AI platforms that plan, execute, and analyze experiments far more efficiently than traditional manual approaches. Bio-pharmaceutical, high value specialty chemical, and advanced materials companies utilize Telescope's products and services to accelerate the development and optimization of chemical processes, thereby cutting down time and costs from lab to market. For more information, please visit www.telescopeinnovations.com.

Forward-Looking Information

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Telescope Innovations to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. These statements relate to future events or future performance and include, but are not limited to, statements regarding the anticipated benefits of the SDL platform, including projected cost savings and development timeline reductions; the Company's expectations regarding commercialization and market expansion of SDL technology; and the Company's ability to adapt its SDL technology for new industry verticals. Such statements reflect management's current expectations and are based on information currently available to management. A number of factors could cause actual events, performance, or results to differ materially from what is projected in the forward-looking statements, including without limitation: the Client's decisions regarding future SDL deployments; technological risks and uncertainties; market acceptance of SDL technology in new sectors; the Company's ability to retain key personnel; general economic conditions; and other risks detailed in the Company's public filings. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284786

Source: Telescope Innovations Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Decade Confirms High Gold-Copper on the Bonaparte Property in Kamloops Mining Division stocknewsapi
DECXF
Highlights of the October 2025 grab sampling program include:

81.3 g/t Au and 1.361% Cu.122.1 g/t Au and 1.087 % Cu.116.8 g/t Au and 2.284% Cu.75.1 g/t Au and 1.165 % Cu.Stewart, British Columbia--(Newsfile Corp. - February 23, 2026) - Decade Resources Ltd. (TSXV: DEC) ("Decade" or the "Company") announces that it has received assay results from sampling on the Bonaparte copper-gold property, located approximately 50km north of Kamloops, B.C., within the Kamloops Mining Division. The Company sent 71 grab samples from an October visit in for assaying that included bedrock quartz-chalcopyrite vein material, hornfelsed argillite wall rock and mineralized dump material from past open pitting activities. Gold assays ranged from 0.001 to 122.1 g/t gold and 0.006 to 2.28 % copper.

The property has different target areas including:

Cu/Au/Mo porphyry potentialBulk-tonnage RIRGS target with high grade gold results in historic drilling, trenching, underground exploration**High grade gold-copper low sulphidation veins systems.Ed Kruchkowski, President of Decade Resources, stated:

"The Bonaparte Gold project is an exciting property located in an area well accessed by a network of logging roads and infrastructure. The Company is very excited to continue with a strategy for advancing the project, which has the potential to add great value for both the Company and the shareholders. As the Company continues compiling all the historic data, it is anticipated that this will aid the designing and completing of drill programs across multiple high-priority gold and copper targets. The Company feels that historic work basically concentrated on the Discovery Zone area which represents an area 300 m wide and 250 m long in the NW corner of the claims and did not explore other compelling targets. The Company plans a multi-phase program including drilling, soil and silt sampling and further geophysics."

The sampling was conducted on exposed quartz-sulphide vein material in open cuts, altered and hornfelsed argillite in the contact areas and mineralized material in dump areas.

Highlights of the October 2025 sampling are shown below:

Sample NumberSample TypeAu g/tAg g/tCu %Bi ppmTe ppm25-BPE-14Grab81.331.831.361124.9133.0325-BPE-15Grab12.934.351.556115.8161.2425-BPE-31Grab122.12591.087321.92>50025-BPE-37Grab126.851.592.84115.26156.8825-BPE-44Grab75.125.931.16553.5971.9725-BPE-62Grab10.173.880.03428.2423.7225-BPE-64Grab42.76.420.01123.8293.5525-BPE-65Grab44.620.360.70239.3960.6625-BPE-70Grab10.7918.390.8699.3418.25Note: The samples above were random in nature but do not necessarily represent the metal content in the source area. The Company feels that the high metal content is highly encouraging and further investigation is warranted.

Samples 25-BPE 14 and 15 were taken from dump material along an overgrown trench on a quartz-chalcopyrite-pyrite vein. Samples BPE 31, 37 and 44 are from dump material left from the previous high grading operations consisting of mixed wall rock and quartz-chalcopyrite-pyrite mineralization. Sample 25-BPE 62 is from a quartz vein with minor chalcopyrite along the east wall of the previous mining pit. Sample 25-BPE 64 and 65 are from sub-crop of the south Crow vein exposed during reclamation and 25-BPE-70 is a sample of quartz-chalcopyrite along the west side of the mining pit.

Highlights of the July 2025 sampling previously released are shown below:

Sample NumberSample TypeAu g/tAg g/tCu %Bi ppmTe ppm25-BP-1Grab175.778.632.267139.63218.8325-BP-3Grab82.335.981.548115.8161.2425-BP-4Grab15.0258.35.9026.2722.8625-BP-5Grab1662.25190.88675.48>50025-BP-7Grab2.450.580.0060.662.1The high bismuth and tellurium values indicate a potential for a RIRGS environment **.

The following map shows the location of Samples 25-BPE 8 to 15 inclusive and 25-BPE 63 to 67 inclusive.

Map is extracted from a 43-101 on the property prepared in 2019 for the previous operators by R. Kemp, P.Geo.

Samples collected in July are shown in a blue colour while the October 2025 sampling is shown in a red colour.

Out of the 71 samples collected in October, 37 assayed > 1 g/t gold while 36 assayed > 0.1 % copper.

The following photo shows the location of sample 25-BPE-27 to 49 inclusive, 25-BPE-53 to 56 inclusive, 25-BPE-59 to 62 inclusive and 25-BPE-68 to 71 inclusive. Sampling from July 2025 is shown in black colour and October 2025 in a red colour.

2026 Strategy to Advance the Gold-Copper Targets

The historic IP surveys successfully delineated a number of anomalous zones and features for Discovery Zone style Au-vein targets, extending southward as well as parallel targets to the east underlying anomalous soil geochemistry. The Discovery Zone contains a series of parallel and sub-parallel gold-bearing quartz veins hosted within a mylonitic shear zone some 250 to 300 meters wide. A basalt cap immediately to the south of the Discovery Zone covers the projected extension of this auriferous zone. Compilation of all historical exploration results have delineated a 2 km long, gold and copper soil geochemistry anomaly extending from the Discovery Zone to the southeast, down the Cooler Creek valley. Outcrop is limited in the valley by glacial till cover. A historic drill hole, 15-05 located roughly 500m east of the Discovery zone area tested a coincident resistivity and Cu-Au soil geochemical anomaly encountering quartz veins in granodiorite similar to those encountered in the "Discovery Zone." Assay results from DDH 15-05 returned 7.88g/t gold, 38.4g/t silver and 0.33% copper over a 1.0m core width. The 1988 soil geochemical surveys along Cooler Creek identified many anomalous Au-Cu soil geochemical anomalies with soil results reporting up to 3,270ppb Au and a rock grab sample of quartz vein material reporting 73.03g/t Au (2.13opt Au).

Existing geophysical data indicates the potential for a large porphyry system situated approximately 1km South of the original Discovery Zone. A second and smaller zone also appears to lie below the original Discovery Zone at depth. Data indicates the larger southerly body begins near the surface and gradually increases in size to approximately 3km wide x 2km wide at approximately 275m depth and then gradually decreases in size to a depth of 500m which is the extent of the geophysical data. Little to no geochemical surveys have been conducted in this area.

The Company QP has not verified the above results and they should not be relied on. They are included as reference data for exploration potential.

The Company is proposing four 1.5 km receiver lines to better define the low resistivity/high chargeability anomaly to the south of the Discovery area. In addition, drilling will test the Discovery area as well as IP anomalies with overlying MMI anomalies over the larger southern low resistivity/high chargeability anomaly. Soil sampling will be conducted east of the Discovery area as well as east of the copper-gold anomalies along Cooler Creek.

Assaying

All samples were prepared at MSA Labs' preparation laboratory in Terrace, B.C., and assayed at MSA Labs' geochemical laboratory in Langley, B.C. Gold was assayed using a fire assay with atomic absorption (AA) spectrometry finish. Samples over 25 parts per million gold were fire assayed with gravimetric finish. All samples were analyzed by four-acid digestion with multielement ICP-MS, with silver and base metal over limits being reanalyzed by emission spectrometry. MSA Labs' quality system complies with the requirements for the international standards ISO 17025 and ISO 9001. MSA Labs is independent of the company.

Qualified Person

Ed Kruchkowski, P.Geo., President of Decade Resources Ltd., is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical contents of this news release. He also conducted the sampling reported in this press release.

About Decade Resources Ltd.

Decade Resources Ltd. is a Canadian based mineral exploration company actively seeking opportunities in the resource sector. Decade holds numerous properties at various stages of development and exploration from basic grass roots to advanced ones. Its properties and projects are mostly located in the "Golden Triangle" area of northern British Columbia. For a complete listing of the Company assets and developments, visit the Company website at www.decaderesources.ca. For investor information please call the Company at 250- 636-2264 or Gary Assaly at 604-377-7969.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including without limitation, that the Company will receive regulatory approval of the Option, the exercise of the Option, exploration plans for the Property and the use of funds for the recently completed private placement are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that Company will be able to receive regulatory approval for the Option, that the Company will be able or willing to make the Option Payments in order to exercise the Option, that the Company will have the necessary funds and resources to conduct its exploration plans on the Property and that the Company will use the proceeds from the private placement as anticipated.

These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the Company is unable to receive regulatory approval for the Option Agreement; that the Company may be unable or unwilling to make all Option Payments and exercise the Option; that the Company may be unable to conduct its exploration plans on the Property as anticipated, or at all; and that the Company may not use the proceeds from the private placement as anticipated.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.

References

Logan, J.M., and Mihalynuk, M.G., 2013. Bonaparte gold: another 195 Ma Au-Cu porphyry deposit in southern British Columbia? In: Geological Fieldwork 2012, British Columbia Ministry of Energy, Mines and Natural Gas. British Columbia Geological Survey Paper 2013-1, 71-80.

Minfile BC

NI 43-101 Technical Report on the Bonaparte Gold Project by R. Kemp, P.Geo.

**Reduced intrusion-related gold systems (RIRGS) are characterized by widespread arrays of sheeted auriferous quartz veins that preferentially form in the brittle carapace at the top of small plutons, where they form bulk-tonnage, low-grade Au deposits characterized by a Au-Bi-Te-W metal assemblage, such as the Fort Knox and Dublin Gulch deposits. https://www.researchgate.net/publication/277131625_Reduced_Intrusion-related_Gold_Systems

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284827

Source: Decade Resources Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC stocknewsapi
RXRX
Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

Presenter Ira Hoffman, CEO of HighRes Biosolutions, will share how they are collaborating with clinical stage AI drug discovery company Recursion on the potential for self-driving, high-throughput labs using advanced automation and orchestration. This collaboration is enabled by HighRes technologies including robotic perception, digital twins of laboratory environments, and natural language-driven lab orchestration that together support the foundation for self-driving laboratories. Other presenters include Fred Parietti, Co-Founder and CEO of Multiply Labs and Olga Ovchinnikova, Director of Product Management, Digital Labs, at Thermo Fisher Scientific.

Recursion has been developing its lab operations for more than a decade, and now operates one of the most sophisticated integrated wet and dry labs for AI drug discovery. The company generates millions of multi-omic data points each week that train its machine learning foundation models to enable end-to-end improvements in the drug discovery process – from novel biological discoveries, to precision drug design, to optimized clinical trials – all powered by Recursion’s NVIDIA-backed supercomputer, BioHive-2.

“Recursion continues to push the frontier of drug discovery through the power of accelerated computing and AI,” said Rory Kelleher, Senior Director, Global Head of Business Development, Healthcare and Life Sciences at NVIDIA. “This year at GTC, we’re collaborating across the ecosystem to move Physical AI from concept to reality, unlocking a new era of biological insight and therapeutic speed.”

Learn more here: https://www.nvidia.com/gtc/session-catalog/sessions/gtc26-s81674/. 

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
Kanata North Fueling Data Centre Promises of Government with Sovereign and Secure Canadian Cloud Infrastructure stocknewsapi
CCDSF
New sovereign cloud solution enables 570+ companies to win government contracts, reduce costs by up to 25%, and accelerate compliance with homegrown winning companies PureColo and ThinkOn

  KANATA, Ontario – February 23, 2026 – TheNewswire - As global data localization requirements intensify and cross-border data flows face increasing restrictions, Canada's largest technology park is positioning its resident companies for unprecedented competitive advantage. The Kanata North Business Association (KNBA) today announces exclusive access to a resilient, made-in-Canada sovereign cloud infrastructure that directly addresses the most pressing challenges facing today's tech innovators. Powered by leading Canadian providers ThinkOn and PureColo, this infrastructure gives Kanata North's 570+ member companies the tools to capture opportunities in Canada's $6.8 billion public sector IT market while significantly reducing operational costs and compliance timelines.

  "This isn't just about data sovereignty – it's about competitive differentiation," said Kelly Daize, Executive Director, KNBA. "Our members can prepare to bid on government contracts previously out of reach, achieve SOC 2 compliance 60% faster than traditional approaches, and reduce cloud costs by over 25% compared to hyperscale alternatives. In a tech park contributing CAD $14 billion annually to Canada's GDP, this represents a transformational opportunity for our 33,000 employees and their companies."

Why This Matters Now

Recent regulatory changes, including Bill C-27 and enhanced provincial privacy laws, are creating new requirements that are more easily achieved using domestically hosted solutions. Meanwhile, geopolitical tensions are driving government and enterprise customers to prefer Canadian-controlled infrastructure.

Immediate Competitive Advantages for Tech Companies

🏆 Unlock Government & Regulated Sector Revenue

●   Government of Canada "Protected B" security clearance ready through PureColo's CISD-certified data centres

●   Accelerated  compliance: PCI DSS, SSAE16 SOC2 Type2, and CSAE3416 Type2, ISO 27001/27107/27018 certifications already in place

●   Win rates increase: Companies report 3x higher success rates in government RFPs when offering Canadian-hosted solutions

💰 Dramatic Cost Reductions

●   More than 25% average savings compared to hyperscale cloud providers

●   Transparent pricing with no hidden fees or egress charges

●   Predictable scaling costs for growing startups and established enterprises

⚡ Superior Performance Where It Counts

●   Sub-2ms latency to major Canadian markets

●   100% uptime SLA backed by 2MW+ redundant power infrastructure

●   Ottawa Internet Exchange hosting provides direct connectivity to 40+ carriers

●   Carrier-neutral environment eliminates vendor lock-in concerns

🚀 Accelerated Time-to-Market

●   AI and ML workloads: Train models on Canadian data without cross-border compliance delays

●   FinTech solutions: Process sensitive financial data with built-in regulatory compliance

●   HealthTech innovations: Handle patient data while meeting strict provincial privacy requirements

●   Defense contractors: Secure infrastructure ready for sensitive government projects

Real-World Impact for Tech Park Companies

For AI Startups: "Train models on Canadian datasets with simplified data governance, avoiding the complexity of cross-border data transfer agreements and regulatory considerations.”

"For FinTech Companies: "Achieve mandatory financial services compliance in weeks, not months, while reducing infrastructure costs by 25%."

For HealthTech Firms: "Deploy patient data solutions that meet both federal and provincial privacy requirements from day one."

For Government Contractors: "Secure infrastructure ready for sensitive government projects."

Strategic Partnership Details

ThinkOn brings enterprise-grade Data Protection as a Service, emphasizing true data sovereignty over "hyperscaler hype." Their solutions feature transparent pricing, robust security, and the ability to keep Canadian data under Canadian control.

PureColo provides the physical foundation with carrier-neutral colocation space with their flagship facility located in the heart of Canada's largest technology research park supporting recognized global brands like Infinera (Nokia), Wind River, Dell, Kinaxis, CIRA, to name a few. Their facilities boast 6MW+ of sovereign infrastructure and is home to the only internet exchange in the region, CANIX. PureColo is a wholly owned subsidiary of public data center aggregator Carrier Connect Data Solutions Inc. (TSXV: CCDS; OTCQB: CCDSF).

  Limited-Time Opportunity for Early Adopters

The initial infrastructure deployment has limited capacity, with priority access reserved for KNBA members. Companies joining the pilot program in Q1 2026 will receive:

●   25% discount on first-year infrastructure costs

●   Priority migration support with dedicated technical teams

●   Compliance consultation to identify immediate opportunities in government and regulated sectors

What Tech Leaders Are Saying

“Cerio is proud to support Canada’s sovereign data centre initiatives with the world’s first scalable Composable Disaggregated Infrastructure (CDI) data centre solution, developed in Canada by Canadians. As a customer of PureColo, we’ve experienced firsthand the strength of their operations and their commitment to building resilient, future‑ready environments”, said Phil Harris, CEO of Cerio.  “We are equally proud to serve as a Canadian technology supplier to world‑class organizations like ThinkON to strengthen the nation’s sovereign digital foundation for the next generation of AI and compute needs. Cerio’s technology enables data centers across the country to lower operational overhead and cost, reduce power and cooling demands, and rapidly integrate new and advanced capabilities to keep Canadians at the forefront of technology.”

  Take Action Now - Click here to begin a discussion with our experts via contact form

Reserve Your Consultation: Limited slots available at the upcoming Kanata North Tech Summit

Join the Pilot Program: Applications open through May 2026.  

About the Kanata North Business Association

Representing over 570 companies in Canada's Largest Technology Park, KNBA drives innovation and business success to ensure that this is the best place in Canada for technology companies to grow, prosper, and thrive.

Media Contacts:

Hannah Manierka, Kanata North BA, 416-460-0799 or [email protected]

Michael Lalonde, PureColo - 613-255-4354 or [email protected]

  About PureColo Inc.

  Purecolo began as a local carrier agnostic data center over 10 years ago in our nation's capital, Ottawa, Canada. The company provides white space to large enterprise clients and SMB’s alike focussing on the three pillars of a top tier data center (power, transit & security). For more information, you may visit their website at:

  https://www.purecolo.ca/

  About ThinkOn Inc.

  ThinkOn is a proudly Canadian-owned cloud service provider specializing in secure, scalable, and sovereign data management. As a channel-only organization, ThinkOn delivers Infrastructure-as-a-Service (IaaS), Disaster Recovery (DRaaS), and Backup (BaaS) solutions tailored for government and enterprise sectors. With a global network of data centers and a deep commitment to data sovereignty, ThinkOn is a trusted partner for sensitive public sector workloads, offering high-touch support and predictable, transparent pricing.

  https://thinkon.com/

  Get Technical Specifications: Visit https://thinkon.com/solutions/ for detailed infrastructure specs

  About Carrier Connect Data Solutions Inc., Parent company of PureColo Inc.

Carrier Connect Data Solutions’ mission is to roll up Tier II/III data centers internationally that specialize in delivering co-location and data center solutions to AI companies, service providers, enterprises and small businesses. Data centers are the physical locations that store computing machines and their related hardware equipment, such as servers, data storage drives, and network equipment. As a carrier-neutral organization, Carrier’s systems are fully independent and owned outright within its leased space. The current principal markets for the Company are Vancouver and Ottawa, Canada and Perth, Australia, where it serves clients who use its facilities either as their primary data center or as an ancillary site depending on their needs.

ON BEHALF OF THE BOARD OF DIRECTORS

  “Mark Binns”

  Mark Binns, CEO

  For further information, please contact:

  Attention:              Mark Binns, CEO

Email:                   [email protected]

Phone:     778-945-1074

  Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Cautionary Statement Regarding Forward-Looking Information

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. “Forward-looking information” includes, but is not limited to, statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. Such forward-looking information is based on numerous assumptions, including among others, that general business and economic conditions will not change in a material adverse manner. Although the assumptions made by the Company in providing forward-looking information are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate. Forward-looking information also involves known and unknown risks and uncertainties and other factors, which may cause actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-looking information or statements, including, among others: negative operating cash flow and dependence on third party financing, uncertainty of additional financing, reliance on key management and other personnel, and the risk factors with respect to the Company set out in the Company’s filings with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers should not place undue reliance on forward-looking statements or information. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.

      
2026-02-23 13:09 19d ago
2026-02-23 08:00 19d ago
First Canadian Graphite Inc. Appoints John LaGourgue as CEO and Board Member stocknewsapi
GBMIF
  Vancouver, BC and Montreal, QC – TheNewswire - February 23, 2026 – First Canadian Graphite Inc. (TSX.V: FCI | Frankfurt: BR2 | OTC: GBMIF) (“First Canadian”, “FCI” or the “Company”), a dynamic junior mining company focused on advancing high-grade graphite projects in Quebec to meet the growing demand for onshore sourced critical minerals, is pleased to announce the appointment of Mr. John LaGourgue as Chief Executive Officer and member of the Board of Directors, effective immediately.

Mr. LaGourgue brings extensive experience in leadership, capital markets, commercial and governmental relations, business development, and operations in the resource sector. He has a proven track record in project oversight, corporate finance, risk management, and commercial operations. This includes over 25 years in senior executive roles, board positions, advisory roles, and investments in private and public companies with a focus on microcap issuers. Mr. LaGourgue has successfully led commercial and mining exploration programs, secured more than $100 million in debt and equity funding, and advanced projects through multiple stages.

John LaGourgue, CEO of First Canadian, stated: “I am honoured to join the FCI team and look forward to driving an exciting new phase for the Company. I see tremendous potential to position First Canadian Graphite as a leader in the global graphite supply chain.  Our world-class graphite district features some of the highest-grade and highest-quality graphitic bodies in existence, located in Quebec’s mining-friendly jurisdiction with excellent road access and global shipping capabilities. These graphitic bodies have drawn me to this opportunity, and my vision is to make First Canadian a premier low-cost, high-quality graphite producer.”  

This appointment aligns with First Canadian's strategic vision to accelerate development of its flagship Berkwood Graphite Project in northern Quebec. The project hosts a high-grade, large-flake graphite resource with a historical NI 43-101 estimate of 3.2 million tonnes of indicated and inferred at an average grade of 17%. It is positioned adjacent to major world-class graphite developments and benefits from Quebec's clean hydroelectric power and supportive infrastructure.

“We are thrilled to welcome John LaGourgue to lead First Canadian at this pivotal time,” said Thomas Yingling, who will focus on his role as President to execute a busy 2026 program of field operations and steps toward commercializing the Company’s resource. “John’s expertise, energy in expanding investor awareness, and clear vision for maximizing shareholder value through commercialization will be instrumental as we advance Berkwood, strengthen our management team and board, and capitalize on the surging global demand for graphite.”

ABOUT FIRST CANADIAN GRAPHITE INC.

First Canadian Graphite Inc. is an exploration Company advancing its flagship Berkwood Graphite Project, located in northern Quebec, Canada.  The Company has a 43-101 Resource Estimate Report revealing 3.2 million tonnes of indicated and inferred graphite, averaging grades of 17%.  

Pessamit Innu First Nation

First Canadian Graphite respectfully acknowledges that the Berkwood Project is located within the traditional territory of the Pessamit Innu First Nation. The Company is committed to fostering respectful, transparent, and collaborative relationships with local Indigenous communities throughout the development process.

Forward-Looking Statements

This press release contains forward-looking statements.  These statements are based on assumptions and beliefs of management and involve risks and uncertainties, which may cause actual results to differ materially from those anticipated.

On Behalf of the Board of Directors

First Canadian Graphite lnc.

Thomas Yingling, President & Director

2200 – 1250 Rene Levesque Blvd. Montreal, QC, H3B 4W8
Phone: (438) 469-0705

#1100 - 1111 Melville Street, Vancouver, BC, V6E 3V6
Phone: (604) 343-7740

FOR MORE INFORMATION, PLEASE CONTACT:

[email protected] or 1-604-343-7740

Website: www.firstcanadiangraphite.com

Disclaimer for Forward-Looking Information: Certain statements in this document which are not purely historical are forward-looking statements, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include that the Company will carry out the drill program described in this news release, conduct the Offering and expend funds on Berkwood Graphite Project exploration. It is important to note that the Company's actual business outcomes and exploration results could differ materially from those in such forward-looking statements. Risks and uncertainties include that further permits may not be granted timely or at all; the mineral claims may prove to be unworthy of further expenditure; there may not be an economic mineral resource; methods we thought would be effective may not prove to be in practice or on our claims; economic, competitive, governmental, environmental and technological factors may affect the Company's operations, markets, products and prices; our specific plans and timing drilling, field work and other plans may change; we may not have access to or be able to develop any minerals because of cost factors, type of terrain, or availability of equipment and technology; and we may also not raise sufficient funds to carry out our plans. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedar.com.  No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them.  These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions, which may prove to be incorrect. Except as required by law, we will not update these forward-looking statement risk factors.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this News Release.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
Applebee's Celebrates 25 Years of Mucho Cocktails with $6 St. Patrick's Day Drinks stocknewsapi
DIN
PASADENA, Calif.--(BUSINESS WIRE)--Applebee's ‘Mucho Madness' is here! To celebrate 25 years of its signature Mucho drink deals, Applebee's is launching two new $6 Mucho cocktails just in time for St. Patrick's Day. Now for a limited time, guests can sip, savor, and celebrate the ‘madness' of the NEW $6 Emerald Escape and NEW $6 Pricklycane – or party with the NEW $4 Parade Punch Mocktail.* A festive fusion of Irish luck and island vibes, guests can enjoy the NEW $6 Emerald Escape, a tropical m.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026 stocknewsapi
AEMD
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.

, /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in real time.

Mr. Frakes will hold a fireside chat and subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event.

Please register here to ensure you are able to attend the conference and receive any updates that are released.

https://goto.webcasts.com/starthere.jsp?ei=1740947&tp_key=dbde48090b&sti=aemd

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device Designation for:

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the Company's planned participation in the Emerging Growth Conference, the anticipated format and availability of the live and archived webcast, and any forward-looking statements that may be made during the Company's presentation, including statements concerning the investigational status of the Hemopurifier®, the progress, timing, design, or potential outcomes of clinical trials, regulatory strategy, manufacturing capabilities, capital requirements, and the advancement of the Company's research and development programs. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to maintain its Nasdaq listing, the Company's ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company's ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company's ability to manage and successfully complete its clinical trials; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company's collaborative research with UCSF Long Covid Clinic; and the Company's ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
[email protected]

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
[email protected] 

SOURCE Aethlon Medical, Inc.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development stocknewsapi
RNAZ
, /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean for Research Development at the College of Human Medicine at Michigan State University and scientific co-founder of TransCode.

The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, such as miRNA-21, as intracellular assembly templates. This approach directly addresses longstanding challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.

"Our findings demonstrate a novel approach to precisely engage innate immune pathways directly within tumor cells, while minimizing systemic toxicity," said Zdravka Medarova, Ph.D., CSO of TransCode. "We believe that combining tumor-specific RNA templating with our TTX nanoparticle delivery platform brings RIG-I-based immunotherapy closer to clinical relevance." TransCode's TTX delivery platform is currently being evaluated in clinical trials, underscoring the translational feasibility of this immunotherapy approach.

Molecular Imaging and Biology is a peer-reviewed scientific journal and the official publication of the World Molecular Imaging Society, focused on translational research in molecular imaging and image-guided therapies with clinical and commercial relevance.

About TransCode Therapeutics 

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode's portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit www.transcodetherapeutics.com.

Forward-Looking Statements 

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the effectiveness of TransCode's TTX delivery platform and its therapeutic approaches and strategies, statements concerning the timing, conduct and results of TransCode's preclinical and clinical studies, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode's therapeutic candidates. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2024, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law. 

SOURCE TransCode Therapeutics, Inc.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
MEDIA ALERT: Equinix to Speak at Upcoming Investor Conferences stocknewsapi
EQIX
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Equinix, Inc. (Nasdaq: EQIX), the world's digital infrastructure company®, today announced that its executives will attend two upcoming investor conferences:

Citi 2026 Global Property CEO Conference on Monday, March 2. Adaire Fox-Martin, CEO and President, will present at 7:30 a.m. ET. Morgan Stanley Technology, Media & Telecom Conference on Monday, March 2. Jon Lin, Chief Business Officer, will present at 11:30 a.m. PT. The presentation will be made available via webcast on the Investor Relations section of the Equinix website at www.equinix.com/investors.

About Equinix
Equinix, Inc. (Nasdaq: EQIX) shortens the path to boundless connectivity anywhere in the world. Its digital infrastructure, data center footprint and interconnected ecosystems empower innovations that enhance our work, life and planet. Equinix connects economies, countries, organizations and communities, delivering seamless digital experiences and cutting-edge AI—quickly, efficiently and everywhere.

SOURCE Equinix, Inc.

Also from this source
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
Mineros Achieves DTC Eligibility, Broadening U.S. Investor Access and Share Liquidity stocknewsapi
MNSAF
MEDELLIN, Colombia--(BUSINESS WIRE)--Mineros S.A. (TSX:MSA, OTCQX:MNSAF, BVC:MINEROS) (“Mineros” or the “Company”) confirms that its common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (“DTC”).

DTC eligibility streamlines the trading process, making it more efficient for investors and brokers. As a subsidiary of the Depository Trust & Clearing Corporation (DTCC), DTC handles electronic clearing and settlement for publicly traded companies. With DTC eligibility, the Company’s shares can now be traded across a wider network of brokerage firms, accelerating the settlement process and improving access for a broader range of investors. This eligibility represents a central component of the Company’s capital markets strategy, intended to modernize share transfer protocols and improve market efficiency for North American investors.

"Attaining DTC eligibility is a significant milestone in our efforts to broaden the Company’s investor base," stated Daniel Henao, President and Chief Executive Officer of Mineros. "By optimizing the electronic trading environment, we are improving share accessibility and strengthening the liquidity profile of Mineros across international public markets."

Strategic Implications for Shareholders

The transition to DTC eligibility removes the administrative requirements associated with the physical handling of stock certificates, offering several institutional advantages:

Enhanced Liquidity: By enabling the seamless electronic execution of trades, the Company expects to reduce transaction friction for brokerage firms. Expanded Market Access: The simplified clearing process facilitates broader participation from both institutional and retail investors within the United States. Operational Efficiency: Electronic settlement standardizes the Company’s trading infrastructure in alignment with global capital market benchmarks. ABOUT MINEROS S.A.

Mineros is a leading Latin American gold mining company headquartered in Medellin, Colombia. The Company has a diversified asset base, with mines in Colombia and Nicaragua and a pipeline of development and exploration projects throughout the region including the La Pepa Project in Chile.

Mineros has more than 50 years of operating history and a longstanding focus on safety, sustainability, and disciplined capital allocation. Its common shares are listed on the Toronto Stock Exchange (MSA) and the Colombia Stock Exchange (MINEROS), and trade on the OTCQX®️ Best Market under the symbol MNSAF.

Election of Directors – Electoral Quotient System

The Company has been granted an exemption from the individual voting and majority voting requirements applicable to listed issuers under Toronto Stock Exchange policies, on grounds that compliance with such requirements would constitute a breach of Colombian laws and regulations which require the directors to be elected on the basis of a slate of nominees proposed for election pursuant to an electoral quotient system. For further information, please see the Company’s most recent annual information form, available on the Company’s website at https://www.mineros.com.co/ and from SEDAR+ at www.sedarplus.com.

FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information includes statements that use forward-looking terminology such as “may”, “could”, “would”, “will”, “should”, “intend”, “target”, “plan”, “expect”, “estimate”, “anticipate”, “believe”, “continue”, “potential”, “view” or the negative or grammatical variation thereof or other variations thereof or comparable terminology. Such forward-looking information includes, without limitation, statements with respect to improved liquidity, simplification of the execution of trades, and wider investor access for a broader range of institutional and retail investors to hold and trade the stock.

Forward-looking information is based upon estimates and assumptions of management in light of management’s experience and perception of current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this news release, including, without limitation, assumptions about: future prices of gold and other metal prices; the accuracy of any mineral reserve and mineral resource estimates; production costs; the price of other commodities such as fuel; equipment or processes operating as anticipated; permitting timelines; political and regulatory stability; the receipt of governmental, regulatory and third party approvals, licenses and permits on favourable terms; obtaining required renewals for existing approvals, requirements under applicable laws; sustained labour stability; stability in financial and capital goods markets; availability of equipment; inflation; exchange rates; and positive relations with local groups. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance that they will prove to be correct. Although the Company has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking information, there may be other factors that cause actions, events, conditions, results, performance or achievements to differ from those anticipated, estimated or intended. For further information of these and other risk factors, please see the “Risk Factors” section of the Company’s annual information form dated March 31, 2025, and management’s discussion and analysis for the three and nine months ended September 30, 2025, available on SEDAR+ at www.sedarplus.com.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information contained herein is made as of the date of this news release and the Company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, future events or results or otherwise, except as and to the extent required by applicable securities laws.

More News From Mineros S.A.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
Johnson Fistel Investigates the Grindr Board for Potential Breaches of Fiduciary Duties Relating to the Grindr Buyout Termination stocknewsapi
GRND
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duty by the Board of Directors of Grindr Inc. (NYSE: GRND).

The investigation concerns the Board’s decision to terminate negotiations with Grindr’s controlling stockholder and whether that decision—and related recent corporate actions—were consistent with the duties owed to all stockholders, particularly minority holders.

We are reviewing whether the Board’s choices may have impacted stockholder rights, including the balance of control at the Company and the treatment of non-controlling investors.

If you own Grindr shares please consider joining our investigation. To participate or learn more, you can click or copy and paste the following link:
https://www.johnsonfistel.com/investigations/grindr-grnd/

Shareholders seeking more information may also contact lead analyst Jim Baker ([email protected], 619-814-4471). If emailing, please include a phone number.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. Stay informed about stock-drop news and learn how Johnson Fistel can help you recover losses by visiting www.johnsonfistel.com. 

Achievement
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected] 
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
FTC Solar Announces Supply Agreement with Lubanzi Inala stocknewsapi
FTCI
AUSTIN, Texas, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, and engineering services, announced today a three-year supply agreement from Lubanzi Inala, a leading South African solar procurement company part of the EPC consortium Green Axis Africa. The initial projects identified under this agreement total approximately 840 megawatts.

“We’re pleased to have been selected by Lubanzi and Green Axis Africa to support their portfolio of 1P and 2P solar projects across South Africa,” said Yann Brandt, President and CEO of FTC Solar. “With a broad portfolio of the fastest and easiest to install trackers in the marketplace, as well as exceptional software and service, we look forward to helping Lubanzi optimize each individual project site.”

“FTC Solar has built a strong set of innovative tracker solutions and is the right partner to support the needs of this diverse project portfolio,” commented Simphiwe Sithole, CEO of Lubanzi Inala. “We look forward to working closely with them as we provide best-in-class quality for our customers and advance the South African renewable energy industry.”

The agreement calls for FTC Solar to supply Lubanzi with approximately 840 megawatts of solar trackers over the 3-year term. The projects are expected to be located in South Africa and utilize a combination of 1P and 2P tracker technologies. The first project under this agreement is expected to begin in mid-2026.

About FTC Solar Inc.
Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a leading provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage.

FTC Solar Investor Contact:
Bill Michalek 
Vice President, Investor Relations 
FTC Solar
T: (737) 241-8618 
E: [email protected]

Forward-Looking Statements 
This press release contains forward looking statements. These statements are not historical facts but rather are based on our current expectations and projections regarding our business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward-looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.  In addition, this press release contains statements about third parties and their commercial activity.  We have not independently verified or confirmed such statements and have instead relied on the veracity of information as provided to us by such third parties related to such statements.  You should not rely on our forward-looking statements or statements related to third parties or their commercial activities as predictions of future events, as actual results may differ materially from those in the forward-looking statements or statements related to third parties or their commercial activities because of several factors, including those described in more detail above and in our filings with the U.S. Securities and Exchange Commission, including the section entitled “Risk Factors” contained therein. FTC Solar undertakes no duty or obligation to update any forward-looking statements or statements related to third parties or their commercial activities contained in this release as a result of new information, future events or changes in its expectations, except as required by law.
2026-02-23 13:09 19d ago
2026-02-23 08:01 19d ago
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile stocknewsapi
CLDX
February 23, 2026 08:01 ET  | Source: Celldex Therapeutics, Inc.

HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, February 27 – March 2.

New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented as a late breaker, highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence.

All presentations will be posted on the Celldex website at the dates/times listed below. Presentation details are as follows:

Trial: Phase 2 ColdU and SD Study
Presentation: Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 072
Location: Convention Center, Level 2, Hall E

Trial: Phase 2 CSU Study
Presentation: Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria
Session Date / Time: 2/27/2026, 2:45 pm - 3:45 pm
Title: Allergic Skin Diseases
Type: Poster Session
Poster Number: 075
Location: Convention Center, Level 2, Hall E

Trial: Phase 2 ColdU and SD Study
Presentation: Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria
Session Date / Time: 3/1/2026, 9:45 am - 10:45 am
Title: Late Breaking Poster Session II
Type: Poster Session LB
Poster Number: L41
Location: Convention Center, Level 2, Hall E

About Barzolvolimab
Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease. Based on data from robust, randomized, placebo controlled Phase 2 studies, barzolvolimab has significant potential as a first in class and best in disease treatment option for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is currently being studied in Phase 3 studies in CSU and ColdU/SD and Phase 2 studies in prurigo nodularis (PN) and atopic dermatitis (AD), with additional indications planned for the future.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Visit www.celldex.com.

Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
[email protected]

Patrick Till
Meru Advisors
(484) 788-8560
[email protected]
2026-02-23 13:09 19d ago
2026-02-23 08:02 19d ago
Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather stocknewsapi
CCI KO T
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

It’s been a fantastic 2026 for most dividend stocks so far this year, but most dividend-payers took a break last week. The Schwab U.S. Dividend Equity ETF was flat while the Consumer Staples SPDR fell 1.8%.

With the stock market opening in about 90 minutes for the week, let’s take a look back at which dividend stocks saw the biggest movements last week.

Broad Market Snapshot Index / ETF Weekly Change SPDR S&P 500 ETF Trust (NYSEARCA:SPY) +1.13% Utilities Select Sector SPDR Fund (NYSEARCA:XLU) -0.37% Consumer Staples Select Sector SPDR Fund (NYSEARCA:XLP) -1.81% Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) 0.00% Dividend Stock Performance: Week of Feb 17-20, 2026 Ticker Company Weekly Change C Citigroup (NYSE:C) +4.64% PEP PepsiCo (NASDAQ:PEP) -0.60% KMI Kinder Morgan (NYSE:KMI) +1.27% MO Altria (NYSE:MO) +0.48% UPS United Parcel Service (NYSE:UPS) -0.72% PG Procter & Gamble (NYSE:PG) +0.44% VZ Verizon Communications (NYSE:VZ) +0.49% KO Coca-Cola (NYSE:KO) +1.47% TGT Target (NYSE:TGT) +0.80% HD Home Depot (NYSE:HD) -2.25% O Realty Income (NYSE:O) +0.73% JNJ Johnson & Johnson (NYSE:JNJ) -0.39% CMCSA Comcast (NASDAQ:CMCSA) -0.73% T AT&T (NYSE:T) -2.47% PFE Pfizer (NYSE:PFE) -3.37% ABBV AbbVie (NYSE:ABBV) -2.89% CCI Crown Castle (NYSE:CCI) -2.62% Key Movers Crown Castle (CCI): DISH Default Shakes a Tower Giant Crown Castle was the week’s most talked-about dividend stock following the company’s February 4th earnings report. CEO Christian Hillabrant confirmed the company had terminated its agreement with DISH Wireless following a default on payment obligations. Crown Castle is now seeking to recover over $3.5 billion in unpaid amounts. That is not a rounding error. That is a structural hole in the revenue model of a company that owns over 40,000 cell towers across the United States.

The sell-side responded quickly. Barclays analyst Brendan Lynch cut his price target to $91 from $101, maintaining an Equal Weight rating, while other analysts including those at Wells Fargo and Jefferies also reduced their targets. The consensus average sits near $100, but the stock has been trading well below that level. CCI pays a quarterly dividend of $1.0625 per share, already reduced from the prior rate of $1.565 per quarter that was cut in early 2025. The DISH default raises fresh questions about tenant concentration risk and whether the dividend is sustainable heading into what management has described as a potential trough year with an expected net loss of $780 million in 2026.

AbbVie (ABBV): Pipeline Strength Meets Policy Headwinds AbbVie dropped nearly 3% on the week despite a string of positive pipeline developments, including FDA approval of its VENCLEXTA plus acalabrutinib combination for previously untreated chronic lymphocytic leukemia. Broader healthcare sector weakness and uncertainty around drug pricing policy weighed on the stock.

AbbVie has increased its dividend for 13 consecutive years, and the most recent quarterly dividend of $1.73 per share reflects a 5.5% increase from the prior rate. Barclays recently initiated coverage with an Overweight rating and a $275 price target, citing underappreciated operating leverage. The long-term dividend story here remains intact, but near-term policy noise is creating volatility.

AT&T (T): Analyst Cuts Add Pressure AT&T slid roughly 2.5% on the week after two major banks trimmed their price targets. Barclays maintained a Hold rating with a $26 price target, reflecting persistent caution about the competitive telecom environment. T-Mobile’s newly announced exclusive access to Starlink’s direct-to-mobile service adds another competitive wrinkle. AT&T pays a quarterly dividend of $0.2775 per share, and the stock still yields close to 4% at current prices. For income investors, AT&T remains a high-yield holding, but the analyst consensus price target of $29.41 suggests limited near-term upside from current levels.

Bright Spots Kinder Morgan (+1.27% on the week): The midstream pipeline operator is up over 20% year to date, supported by strong data center and AI-driven natural gas demand. KMI raised its quarterly dividend to $0.2925 in early 2026. Altria (+0.48% on the week): Up 17% year to date, Altria reaffirmed its 2026 adjusted EPS guidance of $5.56 to $5.72 at the Consumer Analyst Group of New York conference. With a dividend yield near 6.1%, it remains one of the highest-yielding names in the dividend universe. Coca-Cola (+1.47% on the week): A quiet outperformer among consumer staples this week, with analysts at Barclays and UBS maintaining Buy-equivalent ratings. The Bigger Picture and Week Ahead The VIX sits at 20.23, sitting at the boundary between normal and elevated uncertainty. That is not a panic reading, but it is not complacency either. The 10-year Treasury yield is at 4.08%, down from a recent high of 4.29% in early February, which provides some marginal relief for rate-sensitive dividend stocks. The Fed funds rate remains at 3.75%, unchanged since December, with no immediate catalyst for a move in either direction. When investors are chasing growth, defensive income plays tend to sit on the bench. That dynamic was on full display this week.

It’s been an outstanding year so far for most dividend payers as investors flee to stocks that are seen as resistant to AI disruption. We’ll see if that trend continues this week.
2026-02-23 13:09 19d ago
2026-02-23 08:03 19d ago
Furnish Your Way: Article Brings Klarna's Flexible Payments to Furniture Shoppers stocknewsapi
KLAR
TORONTO--(BUSINESS WIRE)--Klarna, the global digital bank and flexible payments provider, today announced a new partnership with Article, a leading modern furniture brand offering thoughtfully designed pieces at great prices. The collaboration brings Klarna's flexible payment options to Article's online checkout across the U.S. and Canada giving shoppers more control when purchasing high-value furniture and décor. Home essentials is one of Klarna's fastest-growing categories in North America, a.
2026-02-23 13:09 19d ago
2026-02-23 08:05 19d ago
QYOU is Now a Badged TikTok Agency Partner stocknewsapi
QYOUF
 Creator marketing company joins TikTok's select group of trusted agency partners

, /PRNewswire/ - QYOU Media (TSXV: QYOU) (OTCQB: QYOUF), a leading creator marketing company built around an integrated approach to creative strategy, storytelling, production and media distribution, today announced it has been badged as a TikTok Agency Partner. The recognition underscores QYOU's expertise at the intersection of creativity and media, and its ability to help brands succeed through creator collaborations, platform-native creative and TikTok-first advertising strategies.

As a TikTok Agency Partner, QYOU is able to help brands build and optimize high-performing TikTok campaigns. QYOU has a proven track record of success on TikTok and is trusted by advertisers to develop TikTok-first campaign strategies to achieve their goals.

QYOU supports brands within entertainment, CPG, gaming, beauty, and other categories in producing and scaling TikTok content across organic and paid strategies. By integrating creator marketing with media, QYOU delivers a unified approach grounded in the platform's most current native best practices.

"TikTok is where culture is created in real time and being recognized as an official Agency Partner is a meaningful milestone for QYOU," said Glenn Ginsburg, President of QYOU Media. "This badge reflects our team's deep understanding of the platform, our creator-first approach, and our ability to build campaigns that drive impact and genuinely connect with audiences."

QYOU has established a strong track record on TikTok, partnering with leading organizations including Paramount Pictures, Kraft Heinz, Disney, and Activision, among others.

Recent accolades highlight QYOU's work across top entertainment and brand partners:

Smile 2 (Paramount Pictures)

Winner, Digiday Streaming & Video Awards – Best Social Video Campaign Winner, Digiday Content Marketing Awards – Best Use of TikTok Silver Honoree & Audience Choice, Shorty Awards - TikTok Category Honoree, Webby Awards - Best Use of Social Media Bronze-Telly Awards- Social Video- Media & Entertainment A Quiet Place: Day One (Paramount Pictures)

Shortlist-Clio Entertainment- Film- Partnerships & Collaborations Gold Winner, ANA Reggie Awards – Influencer Marketing Winner, Digiday Content Marketing Awards – Best Brand/Influencer Collaboration Bronze-Telly Awards- Social Video- Media & Entertainment Assassin's Creed Mirage (Ubisoft)

Winner- Global Influencer Marketing Awards- Best Gaming Campaign 2024 Winner- Digiday Content Marketing Awards- Best Use of TikTok 2024 Paradise (Hulu)

Bronze, Clio Awards - Social Media- Use of Influencer & Talent "Earning TikTok Agency Partner status is a validation of the strategic and creative work our teams deliver every day," said Curt Marvis, CEO of QYOU Media. "As brands increasingly look to TikTok to drive culture, commerce and connection, this partnership positions QYOU to play an even bigger role in shaping what modern creator marketing looks like."

Building on this momentum, QYOU is formalizing and expanding its media practice to further support the distribution and amplification of creator-led content across TikTok. This evolution reflects the company's continued investment in dedicated media expertise and scalable, platform-native solutions that complement its creator-first foundation.

"At TikTok, we are always looking for ways to make it easier for brands and advertisers to develop engaging content and impactful campaigns that resonate with TikTok communities." says Kimberly Wu, Global Head of Marketing Partnerships, TikTok. "We are excited to lean into the media and creative service model with agencies to provide brands with innovative solutions that continue to level up their TikTok campaigns".

QYOU's inclusion in TikTok's Agency Partner Program signals an exciting next chapter for the company as it continues to expand its capabilities, deepen platform partnerships and help brands show up authentically where audiences are most engaged.

For more information about QYOU, visit: https://www.theqyou.com/qyou-tiktok-partner

About QYOU Media
Among the fastest growing creator driven media companies, QYOU Media operates in the United States and India through its subsidiaries, producing, distributing and monetizing content created by social media influencers and digital content stars. Our influencer marketing business in India, Chtrbox, is an influencer and marketing platform and agency, connecting brands/products and social media influencers. In the United States, we power major film studios and streamers, game publishers and consumer brands to create content and market via creators and influencers. The company is founded and managed by industry veterans from Lionsgate, MTV, Disney, Sony and TikTok. Experience our work at www.theqyou.com and at chtrbox.com.

SOURCE QYOU Media Inc.
2026-02-23 13:09 19d ago
2026-02-23 08:05 19d ago
Safe Pro Group Projects Over 500% Year-Over-Year Q1 2026 Revenue Growth Following U.S. Government Award for AI Edge Processing Systems stocknewsapi
SPAI
AVENTURA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Safe Pro Group Inc. (NASDAQ: SPAI) (“Safe Pro” or the “Company”), an artificial intelligence (“AI”) defense technology company delivering drone-powered situational awareness and threat detection solutions, today announced that it expects revenue in the first quarter of 2026 to increase over 500% year-over-year, driven by initial deliveries under a recently awarded U.S. Government subcontract supporting deployment of the Company’s AI-Powered Edge Processing platform.

The Company believes it is entering a commercial and government adoption inflection point, transitioning from development-stage operations into scaling revenue generation and opportunities to access additional government programs.

Operational and Financial Highlights

Based on Preliminary, Unaudited Financial Data, First Quarter 2026 Revenue Growth Expected to be Over 500% Year-over-Year Projected acceleration reflects transition from development-stage operations into revenue-generating government programs Initial U.S. Government Program Revenue Low-Rate Initial Production (LRIP) supports $1,000,000 subcontract awardEstablishes Safe Pro as an active U.S. Government supplierPositions Company for follow-on production and program expansion opportunities Balance Sheet Strengthened Completed $14 million PIPE financing priced at $7.00 per share in Q4 2025Strategic investments led by Ondas Holdings Inc. (NASDAQ: ONDS) and Unusual Machines, Inc. (NYSE American: UMAC)Capital supports manufacturing scale-up, AI deployment, and government contracting execution Commercialization of Patented Safe Pro Object Threat Detection (SPOTD) AI Platform Transition from R&D to deployment and revenue generation phaseAI software performs automated identification of explosive threats from drone imagery at the tactical edgeExpanding integration efforts into widely deployed U.S. Army mission planning and situational awareness ecosystems Expanding Government and Defense Sales Pipeline Active engagements with domestic and allied government agenciesGrowing interest from military and global humanitarian demining organizationsInvitations to participate in multiple U.S. Army-sponsored operational and technology evaluation events “The first quarter of 2026 represents a transformational period for Safe Pro,” said Dan Erdberg, Chairman and Chief Executive Officer of Safe Pro Group Inc. “We believe global demand for AI-enabled drone intelligence and American defense technology is entering a sustained growth cycle. Initial government revenue validates our technology platform and positions Safe Pro for continued operational expansion.”

AI Defense Market Tailwinds

Safe Pro believes global defense modernization, autonomous drone adoption, and AI-enabled battlefield intelligence requirements are creating a structural demand cycle for advanced analytics platforms capable of operating at the tactical edge.

The Company’s patented SPOTD technology enables rapid analysis of drone imagery to identify potential explosive hazards, significantly reducing reliance on manual review while improving mission speed and operator safety.

About Safe Pro Group Inc. (NASDAQ: SPAI)
Safe Pro Group Inc. is an AI-driven defense and security technology company providing drone imagery analytics, situational awareness solutions, and protective technologies for government, humanitarian, and homeland security customers worldwide.

Its ecosystem integrates:

SPOTD AI threat detection softwareDrone-based data acquisition and analysisProtective balisitc equipmentFlexible technology archtectures leveraging the hyperscalablity of the Amazon Web Services (AWS) Cloud and local, hardware-based hypercompute edge processing The Company’s technologies enable faster identification of explosive threats and operational risks across defense, law enforcement, critical infrastructure and post-conflict humanitarian environments. To learn more about Safe Pro Group, its subsidiaries, and technologies, please visit https://safeprogroup.com and connect with us on LinkedIn, Facebook, and X.

Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements relate to future events, future expectations, plans and prospects and in this press release include, without limitation, the Company's projected 500% revenue increase for Q1 2026, Safe Pro’s ability to generate revenue from the sales of its products, its ability to support current and future customers, statements regarding commercialization and recurring revenue generation, market opportunities, business momentum, and the expected contribution of the Government Contract to revenue. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth under Item 1A. in the Company’s most recently filed Form 10-K and updated from time to time in the Company’s Form 10-Q filings and in other filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: the Company's limited operating history and history of losses; the Company's ability to successfully execute on government contracts; risks related to government contracting including contract modifications, delays, or cancellations; the Company's ability to scale operations; market acceptance of the Company's products; competition; technological changes; the Company's reliance on third-party technology providers including AWS; regulatory compliance; and general economic conditions. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Media Relations for Safe Pro Group Inc.:
[email protected]

Investor Contact:
Ankit Hira, Managing Director
Solebury Strategic Communications for Safe Pro Group Inc.
[email protected]
2026-02-23 13:09 19d ago
2026-02-23 08:07 19d ago
Alphabet: SpaceX IPO, 100-Year Bond, And My New Understanding Of Its Moat stocknewsapi
GOOG GOOGL
Alphabet delivered a double beat in FQ4, but updated CAPEX guidance for 2026 caused market concerns. These concerns are short-sighted. GOOG's investment in SpaceX and 100-year bond offering illustrates its long-term moat: a dual-track strategy combining robust current income and high-risk bets.
2026-02-23 13:09 19d ago
2026-02-23 08:08 19d ago
Strong price gains in gold, silver, on safe-haven bids stocknewsapi
AAAU BAR DBP DGL GLD GLDM IAU OUNZ SGOL SIL SILJ SIVR SLV SLVP UGL
Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another.

Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a technical analyst for Dow Jones Newswires and as the senior market analyst with TraderPlanet.com. Jim is also a consultant with the highly respected "Pro Farmer" agricultural advisory service. Jim was also the head equities analyst at CapitalistEdge.com. He received his degree from Iowa State University in Ames, Iowa, where he studied journalism and economics.

Follow Jim daily on Kitco.com as he provides both AM and PM roundups and a daily Technical Special. 1 877 963-NEWS jwyckoff at kitco.com
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Stepan Reports Fourth Quarter and Full Year 2025 Results stocknewsapi
SCL
, /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported:

Fourth Quarter 2025 Highlights

Reported net income was $5.0 million, up 49% versus the prior year.   Adjusted net income(1) was a $0.5 million loss, down 119% versus the prior year, largely due to higher interest expense, resulting from lower capitalized interest income recognition due to the Pasadena, TX site start-up, a less favorable effective tax rate and lower Surfactant earnings.  EBITDA(2)  was $43.3 million, up 21% versus the prior year.  Adjusted EBITDA(2) was $33.8 million, down 3% year-over-year. Global sales volume was down 3% year-over-year.  Global sales volume, excluding the impact of the Philippines asset divestiture, was flat year-over-year.     Cash from Operations was $60.0 million during the quarter.  Free cash flow(3) for the quarter was $25.4 million, driven by a reduction in working capital. Pre-tax earnings include $6.2 million of goodwill impairment expense related to the Company's Mexican reporting unit and $15.9 million of gains related to the previously announced Philippines and Lake Providence, LA asset divestitures. Full Year 2025 Highlights

Reported net income was $46.9 million, down 7% versus the prior year.  Adjusted net income(1) was $41.7 million, down 17% versus the prior year. EBITDA(2)  was $208.0 million and Adjusted EBITDA(2) was $198.9 million, up 11% and 6%, respectively, year-over-year. Global sales volume was up 1% year-over-year.  Global sales volume, excluding the impact of the Philippines asset divestiture, was up 2% year-over-year.   "2025 was a transformational year for Stepan as we divested two plant sites and completed preliminary work that has positioned us to further optimize our footprint and asset base in 2026.  Despite many challenges in 2025, we delivered growth in several of our core businesses, advanced several strategic initiatives and have an operational plan in place to accelerate profitable growth moving forward.  Full year adjusted EBITDA grew 6% versus prior year despite a significant increase in oleochemical raw material costs and start-up expenses at our Pasadena site.  Volume grew 1%, organic volume grew 2% and net sales were up 7% driven by pricing actions and favorable product and customer mix.  We delivered $25.4 million of free cash flow and increased our dividend for the 58th consecutive year, while reducing our Net Debt by $31.7 million and our Leverage Ratio to 2.5," said Luis E. Rojo, President and Chief Executive Officer.  "Fourth quarter adjusted EBITDA was down 3% primarily due to a challenging North American Surfactant environment.  We continue to recover margins in Surfactants despite an unprecedented run-up in raw material costs.  Polymer volume was up 11% as our Rigid, Specialty Polyols and Phthalic Anhydride businesses all delivered volume growth.  I want to personally thank all of our Stepan colleagues around the world for their hard work and resilience during the year."

Financial Summary

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands, except per share data)

2025

2024

%
Change

2025

2024

%
Change

Net Sales

$

553,886

$

525,609

5

%

$

2,332,114

$

2,180,274

7

%

Operating Income

$

10,502

$

7,695

36

%

$

78,549

$

70,480

11

%

Net Income

$

5,004

$

3,350

49

%

$

46,895

$

50,370

(7)

%

Earnings per Diluted Share

$

0.22

$

0.15

47

%

$

2.05

$

2.20

(7)

%

Adjusted Net Income *

$

(531)

$

2,757

(119)

%

$

41,680

$

50,470

(17)

%

Adjusted Earnings per
   Diluted Share *

$

(0.02)

$

0.12

(117)

%

$

1.82

$

2.20

(17)

%

* See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.

Percentage Change in Net Sales

Net sales in the fourth quarter of 2025 increased 5% year-over-year.  This increase reflects higher selling prices, that were mainly attributable to the pass-through of higher raw material costs and more favorable product mix, and the favorable impact of foreign currency translation.  A 3% decline in sales volume partially offset the above.   

Three Months Ended
December 31, 2025

Twelve Months Ended
December 31, 2025

Volume

(3)

%

1

%

Selling Price & Mix

5

%

6

%

Foreign Translation

3

%

(—)

%

Total

5

%

7

%

Segment Results

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands)

2025

2024

%
Change

2025

2024

%
Change

Net Sales

Surfactants

$

401,832

$

378,776

6

%

$

1,665,983

$

1,532,115

9

%

Polymers

$

131,682

$

129,844

1

%

$

584,477

$

584,905

(0)

%

Specialty Products

$

20,372

$

16,989

20

%

$

81,654

$

63,254

29

%

Total Net Sales

$

553,886

$

525,609

5

%

$

2,332,114

$

2,180,274

7

%

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands, all amounts pre-tax)

2025

2024

%
Change

2025

2024

%
Change

Operating Income

Surfactants

$

9,343

$

16,173

(42)

%

$

67,358

$

85,618

(21)

%

Polymers

$

3,984

$

3,396

17

%

$

43,265

$

40,623

7

%

Specialty Products

$

5,240

$

5,594

(6)

%

$

25,640

$

20,908

23

%

Total Segment
   Operating Income

$

18,567

$

25,163

(26)

%

$

136,263

$

147,149

(7)

%

Corporate Expenses

$

(8,065)

$

(17,468)

(54)

%

$

(57,714)

$

(76,669)

(25)

%

Consolidated
   Operating Income

$

10,502

$

7,695

36

%

$

78,549

$

70,480

11

%

Three Months Ended
December 31,

Year Ended
December 31,

($ in millions)

2025

2024

%
Change

2025

2024

%
Change

EBITDA

$

43.3

$

35.8

21

%

$

208.0

$

186.9

11

%

Adjusted EBITDA

   Surfactants

$

32.1

$

34.7

(7)

%

$

153.0

$

157.6

(3)

%

   Polymers

$

12.4

$

11.4

9

%

$

76.4

$

73.0

5

%

   Specialty Products

$

6.7

$

7.1

(6)

%

$

31.5

$

26.9

17

%

   Unallocated Corporate

$

(17.4)

$

(18.2)

(4)

%

$

(62.0)

$

(70.5)

(12)

%

Consolidated Adjusted EBITDA

$

33.8

$

35.0

(3)

%

$

198.9

$

187.0

6

%

Consolidated adjusted EBITDA(2) decreased $1.2 million, or 3%, in the quarter.  This decrease was primarily due to a 7% decline in Surfactant sales volume, driven by lower demand in the global commodity Laundry & Cleaning end markets.  Polymer sales volume growth of 11% and lower corporate expenses partially offset the above. 

Surfactant net sales were $401.8 million for the quarter, a 6% increase versus the prior year.  Selling prices were up 10% primarily due to pass through of higher raw material costs, improved product and customer mix, along with pricing actions.  Sales volume declined 7% year-over-year primarily due to lower demand within the commodity Laundry & Cleaning end markets, lower demand from our distribution partners and lower volume in the Philippines due to the asset divestiture.  Excluding the impact of the Philippines, organic volume declined 3%.  These declines were partially offset by double digit growth within the Industrial Cleaning end markets and year-over-year growth within the Agricultural and Oilfield end markets.  Foreign currency translation positively impacted net sales by 3%.  Surfactant adjusted EBITDA(2)  for the quarter decreased $2.6 million, or 7%, versus the prior year.  This decrease was primarily due to the 7% decrease in sales volume.  Polymer net sales were $131.7 million for the quarter, a 1% increase versus the prior year.  Selling prices decreased 12%, primarily due to the pass-through of lower raw material costs and competitive pressures.  Sales volume increased 11% in the quarter.  North American Rigid and commodity Phthalic Anhydride sales volume was up double digits year-over-year.  Foreign currency translation positively impacted net sales by 2% during the quarter.  Polymer adjusted EBITDA(2) increased $1.0 million, or 9%, versus the prior year primarily due to the 11% increase in sales volume.     Specialty Products net sales were $20.4 million for the quarter, a 20% increase versus the prior year, primarily due to higher sales volume.  Specialty Products adjusted EBITDA(2) decreased $0.4 million, or 6%.  The decrease in adjusted EBITDA(2) was primarily due to lower margins resulting from order timing fluctuations within the pharmaceutical business. Income Taxes

The Company's effective tax rate was 21.7% in 2025 versus 16.7% in 2024.  This increase was primarily attributable to the non-recurrence of favorable deferred tax adjustments recognized in 2024.

Outlook

"As we look forward to 2026, we remain focused on delivering superior shareholder returns with a balanced approach between top line growth and productivity cost out efforts.  Today we announced Project Catalyst, which is a comprehensive plan designed to further optimize our asset base and create a more productive and agile organization to enable growth.  Project Catalyst is expected to deliver approximately $100 million in pre-tax savings over the next two years.  As part of Project Catalyst, Stepan will close its Fieldsboro, NJ site and decommission select assets at its Millsdale, IL and Stalybridge, UK facilities.  Additionally, we are analyzing other opportunities to optimize our asset base, organization structure and operating model.  We will announce future interventions once approved plans are in place,"  said Luis E. Rojo, President and Chief Executive Officer.  "With these actions, we believe we are positioned to deliver full year Adjusted EBITDA growth and positive free cash flow in 2026, despite the ongoing market and tariff uncertainties."

Notes

(1) Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.

(2) EBITDA and adjusted EBITDA are non-GAAP measures.  See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA.

(3) Free cash flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures.  Cash generated from operations was $60.0 million during the fourth quarter of 2025 and capital expenditures were $34.6 million. 

Conference Call

Stepan Company will host a conference call to discuss its third quarter results at 9:00 a.m. ET (8:00 a.m. CT) on February 23, 2026. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN.  To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time.  The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

Supporting Slides

Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.

Corporate Profile

Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia. 

The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com

More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com. 

Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to  accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, changes in global trade policies, including tariffs; legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.  In addition to the risks described in the Company's periodic reports, the restructuring actions described herein may involve risks related to the execution of facility closures and asset decommissioning, potential operational disruptions, impacts on employees and local communities, environmental compliance, and the realization of anticipated cost savings and efficiencies.

These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

* * * * *

Tables follow

Table I

STEPAN COMPANY

For the Three and Twelve Months Ended December 31, 2025 and 2024

(Unaudited – in 000's, except per share data)

Three Months Ended
December 31,

Twelve Months Ended
December 31,

2025

2024

2025

2024

Net Sales

$

553,886

$

525,609

$

2,332,114

$

2,180,274

Cost of Sales

502,369

468,913

2,062,226

1,908,060

Gross Profit

51,517

56,696

269,888

272,214

Operating Expenses:

Selling

10,703

11,018

48,767

45,628

Administrative

23,710

24,764

90,789

98,277

Research, Development and Technical Services

15,703

13,793

59,278

55,674

Deferred Compensation Expense

549

(574)

2,155

2,155

50,665

49,001

200,989

201,734

Goodwill Impairment

6,245

-

6,245

-

Gain on sale of assets

(15,895)

-

(15,895)

Operating Income

10,502

7,695

78,549

70,480

Other Income (Expense):

Interest, Net

(5,689)

(4,829)

(22,115)

(14,182)

Other, Net

126

(410)

3,470

4,141

(5,563)

(5,239)

(18,645)

(10,041)

Income Before Provision for Income Taxes

4,939

2,456

59,904

60,439

Provision for Income Taxes

(65)

(894)

13,009

10,069

Net Income

5,004

3,350

46,895

50,370

Net Income Per Common Share

Basic

$

0.22

$

0.15

$

2.05

$

2.21

Diluted

$

0.22

$

0.15

$

2.05

$

2.20

Shares Used to Compute Net Income Per
   Common Share

Basic

22,878

22,841

22,872

22,832

Diluted

22,891

22,912

22,890

22,931

Table II

Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share*

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands, except per share amounts)

2025

EPS

2024

EPS

2025

EPS

2024

EPS

Net Income Reported

$

5,004

$

0.22

$

3,350

$

0.15

$

46,895

$

2.05

$

50,370

$

2.20

Deferred Compensation (Income)

$

76

$

0.01

$

(762)

$

(0.03)

$

(473)

$

(0.02)

$

(1,805)

$

(0.08)

Environmental Remediation
    Expense

$

65

$

0.00

$

169

$

-

$

934

$

0.04

$

1,905

$

0.08

Goodwill Impairment

$

6,245

$

0.27

$

-

$

-

$

6,245

$

0.27

$

-

$

-

Gain on Sale of Assets

$

(11,921)

$

(0.52)

$

-

$

-

$

(11,921)

$

(0.52)

$

-

$

-

Adjusted Net Income

$

(531)

$

(0.02)

$

2,757

$

0.12

$

41,680

$

1.82

$

50,470

$

2.20

* All amounts in this table are presented after-tax

The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition.  The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators.  Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years.  These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies.  The Company's Annual Report on Form 10-K for the year ended December 31, 2024 contains additional information regarding the use of non-GAAP financial measures.

Summary of Fourth Quarter 2025 Adjusted Net Income Items

Adjusted net income excludes non-operational deferred compensation income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.

Deferred Compensation: The fourth quarter of 2025 reported net income includes $0.1 million of after-tax expense versus $0.8 million of after-tax income in the prior year.  Environmental Remediation: The fourth quarter of 2025 reported net income includes $0.1 million of after-tax expense versus $0.2 million of after-tax expense in the prior year. Goodwill Impairment: The fourth quarter of 2025 reported net income includes $6.2 million of after-tax expense related to a goodwill impairment charge taken for the Company's Mexican reporting unit.  There were no impairment charges taken in the prior year. Gain on Sale of Assets: The fourth quarter of 2025 reported net income includes $11.9 million of after-tax income related to the previously announced Philippines and Lake Providence, LA asset sales. Table III

Reconciliation of Pre-Tax to After-Tax Adjustments

Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.  The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands, except per share amounts)

2025

EPS

2024

EPS

2025

EPS

2024

EPS

Pre-Tax Adjustments

Deferred Compensation (Income)

$

101

$

(1,016)

$

(631)

$

(2,406)

Environmental Remediation Expense

$

87

$

225

$

1,245

$

2,540

Goodwill Impairment

$

6,245

$

-

$

6,245

$

-

Gain on Sale of Assets

$

(15,895)

$

-

$

(15,895)

$

-

   Total Pre-Tax Adjustments

$

(9,462)

$

(791)

$

(9,036)

$

134

Cumulative Tax Effect on Adjustments

$

3,927

$

198

$

3,821

$

(34)

After-Tax Adjustments

$

(5,535)

$

(0.24)

$

(593)

$

(0.03)

$

(5,215)

$

(0.23)

$

100

$

0.00

Table IV

Deferred Compensation Plans

The full effect of the deferred compensation plans on quarterly pre-tax income was $0.1 million of expense versus $1.1 million of income in the prior year.  The quarter-end market prices of Company stock and the impact of deferred compensation on specific income statement line items is summarized below:

2025

2024

12/31

9/30

6/30

3/31

12/31

9/30

6/30

3/31

Stepan Company

$

47.36

$

47.70

$

54.58

$

55.04

$

64.70

$

77.25

$

83.96

$

90.04

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands)

2025

2024

2025

2024

Deferred Compensation

Operating Income (Expense)

$

(549)

$

574

$

(2,155)

$

(2,155)

Other, net – Mutual Fund Gain (Loss)

448

442

2,786

4,561

Total Pre-Tax

$

(101)

$

1,016

$

631

$

2,406

Total After-Tax

$

(76)

$

762

$

473

$

1,805

Effects of Foreign Currency Translation

The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period.  The table below presents the impact that foreign currency translation had on select income statement line items. 

($ in millions)

Three Months Ended
December 31,

Change

Change
Due to
Foreign
Currency
Translation

Twelve Months Ended
December 31,

Change

Change
Due to
Foreign
Currency
Translation

2025

2024

2025

2024

Net Sales

$

553.9

$

525.6

$

28.3

$

16.1

$

2,332.1

$

2,180.3

$

151.8

$

4.6

Gross Profit

51.5

56.7

$

(5.2)

1.5

269.9

272.2

$

(2.3)

(0.4)

Operating Income

10.5

7.7

$

2.8

0.7

78.5

70.5

$

8.0

(0.8)

Pretax Income

4.9

2.5

$

2.4

0.5

59.9

60.4

$

(0.5)

(1.1)

Corporate Expenses

Three Months Ended
December 31,

Twelve Months Ended
December 31,

($ in thousands)

2025

2024

%
Change

2025

2024

%
Change

Total Corporate Expenses

$

8,065

$

17,468

(54)

%

$

57,714

$

76,669

(25)

%

Less:

   Deferred Compensation Expense

$

549

$

(574)

(196)

%

$

2,155

$

2,155

(—)

%

   Environmental Remediation
      Expense

$

87

$

225

(61)

%

$

1,245

$

2,540

(51)

%

  Goodwill Impairment

$

6,245

$

-

NM

$

6,245

$

-

NM

  Gain on Sale of Assets

$

(15,895)

$

-

NM

$

(15,895)

$

-

NM

Adjusted Corporate Expenses

$

17,079

$

17,817

(4)

%

$

63,964

$

71,974

(11)

%

Adjusted Corporate expenses decreased $0.7 million, or 4% for the quarter.  This decrease was primarily due to the non-recurrence of CEO transition expenses in the fourth quarter of 2024.

Table V

Stepan Company

Consolidated Balance Sheets

December 31, 2025 and December 31, 2024

December 31, 2025

December 31, 2024

ASSETS

Current Assets

$

858,959

$

810,429

Property, Plant & Equipment, Net

1,219,627

1,198,454

Other Assets

279,116

295,765

Total Assets

$

2,357,702

$

2,304,648

LIABILITIES AND STOCKHOLDERS' EQUITY     

Current Liabilities

$

666,494

$

669,034

Deferred Income Taxes

11,450

9,612

Long-term Debt

340,975

332,632

Other Non-current Liabilities

94,773

123,436

Total Stepan Company Stockholders' Equity

1,244,010

1,169,934

Total Liabilities and Stockholders' Equity

$

2,357,702

$

2,304,648

Selected Balance Sheet Information 

The Company's total debt decreased by $28.8 million and cash increased by $14.2 million versus September 30, 2025.  The Company's net debt level decreased $43.0 million versus September 30, 2025 and the net debt ratio was 28% versus 30% in the prior quarter (Net Debt and Net Debt Ratio are non-GAAP measures, reconciliations of which are shown in the table below).  Management uses the non-GAAP net debt metric to show a more complete picture of the Company's overall liquidity, financial flexibility and leverage level. 

($ in millions)

December 31,
2025

September 30,
2025

June 30,
2025

March 31,
2025

December 31,
2024

Net Debt

Total Debt

$

626.7

$

655.5

$

658.0

$

659.3

$

625.4

Cash

132.7

118.5

88.9

107.5

99.7

Net Debt

$

494.0

$

537.0

$

569.1

$

551.8

$

525.7

Equity

1,244.0

1,246.8

1,241.7

1,200.5

1,169.9

Net Debt + Equity

$

1,738.0

$

1,783.8

$

1,810.8

$

1,752.3

$

1,695.6

Net Debt / (Net Debt + Equity)     

28

%

30

%

31

%

31

%

31

%

The major working capital components were:

($ in millions)

December 31,
2025

September 30,
2025

June 30,
2025

March 31,
2025

December 31,
2024

Net Receivables

$

388.0

$

436.1

$

442.2

$

436.5

$

388.0

Inventories

298.8

324.3

329.5

309.3

288.7

Accounts Payable     

(261.7)

(289.4)

(281.8)

(298.1)

(258.8)

$

425.1

$

471.0

$

489.9

$

447.7

$

417.9

Table VI

Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA

Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.  Refer to the Income Statement on Table I for a bridge between Operating Income and Net Income.

Three Months Ended
December 31, 2025

($ in millions)

Surfactants

Polymers

Specialty
Products

Unallocated
Corporate

Consolidated

Operating Income

$

9.4

$

4.0

$

5.2

$

(8.1)

$

10.5

   Depreciation and Amortization     

22.7

8.4

1.5

0.1

32.7

   Other, Net Income

-

-

-

0.1

0.1

EBITDA

$

43.3

   Deferred Compensation

-

-

-

0.1

0.1

   Environmental Remediation

-

-

-

0.1

0.1

   Goodwill Impairment

-

-

-

6.2

6.2

   Gain on Sale of Assets

-

-

-

(15.9)

(15.9)

Adjusted EBITDA

$

32.1

$

12.4

$

6.7

$

(17.4)

$

33.8

Three Months Ended
December 31, 2024

($ in millions)

Surfactants

Polymers

Specialty
Products

Unallocated
Corporate

Consolidated

Operating Income

$

16.2

$

3.4

$

5.6

$

(17.5)

$

7.7

   Depreciation and Amortization

18.5

8.0

1.5

0.5

28.5

   Other, Net Income

-

-

-

(0.4)

(0.4)

EBITDA

$

35.8

   Deferred Compensation

-

-

-

(1.0)

(1.0)

   Environmental Remediation

-

-

-

0.2

0.2

Adjusted EBITDA

$

34.7

$

11.4

$

7.1

$

(18.2)

$

35.0

Twelve Months Ended
December 31, 2025

($ in millions)

Surfactants

Polymers

Specialty
Products

Unallocated
Corporate

Consolidated

Operating Income

$

67.4

$

43.3

$

25.6

$

(57.8)

$

78.5

   Depreciation and Amortization

85.6

33.1

5.9

1.4

126.0

   Other, Net Income

-

-

-

3.5

3.5

EBITDA

$

208.0

   Deferred Compensation

-

-

-

(0.6)

(0.6)

   Environmental Remediation

-

-

-

1.2

1.2

   Goodwill Impairment

-

-

-

6.2

6.2

   Gain on Sale of Assets

-

-

-

(15.9)

(15.9)

Adjusted EBITDA

$

153.0

$

76.4

$

31.5

$

(62.0)

$

198.9

Twelve Months Ended
December 31, 2024

($ in millions)

Surfactants

Polymers

Specialty
Products

Unallocated
Corporate

Consolidated

Operating Income

$

85.6

$

40.6

$

20.9

$

(76.6)

$

70.5

   Depreciation and Amortization

72.0

32.4

6.0

1.9

112.3

   Other, Net Income

-

-

-

4.1

4.1

EBITDA

$

186.9

   Deferred Compensation

-

-

-

(2.4)

(2.4)

   Environmental Remediation

-

-

-

2.5

2.5

Adjusted EBITDA

$

157.6

$

73.0

$

26.9

$

(70.5)

$

187.0

SOURCE Stepan Company
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide stocknewsapi
LH
AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care

, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.

Photo courtesy of Labcorp "Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," said Dr. Marcia Eisenberg, chief scientific officer at Labcorp. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers."

Labcorp will deploy AISight Dx across its anatomic pathology labs and hospital collaborations, enabling fully digital workflows for case management, slide review, collaboration and annotation. The platform also integrates AI-powered image analysis, secure storage and system connectivity to deliver faster turnaround, greater efficiency, reliable quality and improved collaboration. Labcorp will also incorporate digital pathology workflows in support of its precision medicine products.

"Labcorp's leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI," said Dr. Andy Beck, co-founder and CEO of PathAI. "The deployment of AISight Dx across Labcorp's network brings high-quality, efficient digital pathology to a national scale."

The expansion builds on Labcorp's 2019 strategic investment in PathAI, a collaboration that has since advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.

To learn more about Labcorp's digital pathology capabilities, visit https://www.labcorp.com/disciplines/digital-pathology-and-artificial-intelligence-ai

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

1 AISight® Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected deployment and benefits of the Path AI AISight Dx digital pathology platform.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

SOURCE Labcorp
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Winnebago Industries to Participate in Fireside Chat at the Raymond James 2026 Institutional Investors Conference stocknewsapi
WGO
EDEN PRAIRIE, Minn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, today announced that Senior Vice President and Chief Financial Officer Bryan Hughes and Joan Ondala, Vice President, Treasury and Investor Relations, will participate in an analyst‑led fireside chat and conduct one‑on‑one meetings at the Raymond James 2026 Institutional Investors Conference in Orlando, Florida.

The fireside chat will take place on Monday, March 2, 2026, at 9:50 a.m. ET. A live webcast of the event will be available on Winnebago Industries’ investor relations website at https://investor.wgo.net. The webcast will be archived and available for replay for 90 days following the event.

Please contact Raymond James for attendance information and additional details.

About Winnebago Industries

Winnebago Industries, Inc. is a leading North American manufacturer of outdoor lifestyle products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota, and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries' investor relations material or to add your name to an automatic email list for Company news releases, visit https://investor.wgo.net.

Contacts

Investors: Joan Ondala
[email protected]

Media: Dan Sullivan
[email protected]
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Arvinas to Participate in Upcoming Investor Conferences stocknewsapi
ARVN
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences:

TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here, at 1:10 p.m. ET.Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here, at 4:20 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here, at 11:00 a.m. ET.2026 Jefferies Biotech on the Beach Summit on Wednesday, March 11. Replays of the fireside chats will be available on the Events and Presentations section of the Company’s website.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]

Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Syndax Announces Participation in March Investor Conferences stocknewsapi
SNDX
February 23, 2026 07:00 ET  | Source: Syndax Pharmaceuticals, Inc.

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.Leerink Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 12, 2026, at 11:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Western Midstream Announces Fourth-Quarter Post-Earnings Interview with CFO, Kristen Shults stocknewsapi
WES
and Participation in Upcoming Investor Conferences

, /PRNewswire/ -- Today Western Midstream Partners, LP (NYSE: WES) ("WES" or the "Partnership") announced that tomorrow before the market open it will make available on its website at www.westernmidstream.com a post-earnings interview with Kristen Shults, Senior Vice President and Chief Financial Officer that provides additional insights related to WES's full-year and fourth-quarter 2025 results and 2026 outlook.

WES intends to participate in the following investor conferences during the first and second quarters of 2026:

Morgan Stanley Energy & Power Conference, in New York, New York, on March 3, 2026 Barclays IG Energy & Utilities Corporate Days, in New York, New York, on March 4, 2026 NYSE Investor Access Energy & Utilities Day (Virtual) on March 19, 2026 US Capital Advisors 15th Annual Midstream Corporate Access Day in Houston, Texas on April 1, 2026 The 23rd Annual Energy Infrastructure CEO & Investor Conference in Adventura, Florida, on May 19 – 20, 2026 ABOUT WESTERN MIDSTREAM

Western Midstream Partners, LP ("WES") is a master limited partnership formed to develop, acquire, own, and operate midstream assets. With midstream assets located in Texas, New Mexico, Colorado, Utah, and Wyoming, WES is engaged in the business of gathering, compressing, treating, processing, and transporting natural gas; gathering, stabilizing, and transporting condensate, natural-gas liquids, and crude oil; and gathering, transporting, recycling, treating, and disposing of produced water for its customers. In its capacity as a natural-gas processor, WES also buys and sells residue, natural-gas liquids, and condensate on behalf of itself and its customers under certain gas processing contracts. A substantial majority of WES's cash flows are protected from direct exposure to commodity price volatility through fee-based contracts. 

For more information about WES, please visit www.westernmidstream.com. 

WESTERN MIDSTREAM CONTACTS

Daniel Jenkins
Director, Investor Relations                    
[email protected]
866-512-3523

Rhianna Disch
Manager, Investor Relations
[email protected]
866-512-3523

SOURCE Western Midstream Partners, LP
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Greenland Technologies Holding Corporation Announces Effective Date of Dual-Class Share Structure stocknewsapi
GTEC
, /PRNewswire/ -- Greenland Technologies Holding Corporation (Nasdaq: GTEC) ("Greenland" or the "Company"), a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles, today announced that its dual-class share structure will become effective on the Nasdaq Capital Market on February 24, 2026.

In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the ordinary shares of no par value in the Company were re-designated into class A ordinary shares of no par value which will carry one vote each (the "Class A Ordinary Shares") and class B ordinary shares of no par value which will carry 25 votes per share.

The Company anticipates that beginning with the opening of trading on February 24, 2026, the Class A Ordinary Shares will trade on the Nasdaq Capital Market under the same symbol "GTEC" and the same CUSIP number G4095T107.

About Greenland Technologies Holding Corporation

Greenland Technologies Holding Corporation (Nasdaq: GTEC) is a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles. For more information, please visit the Company's website at https://ir.gtec-tech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except to the extent required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's quarterly report on Form 10-Q, filed with the SEC on November 7, 2025, and other filings with the U.S. Securities and Exchange Commission.

SOURCE Greenland Technologies Holding Corporation
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference stocknewsapi
APLS
February 23, 2026 07:00 ET  | Source: Apellis Pharmaceuticals, Inc.

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.

The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact:
Eva Stroynowski
[email protected]
617.938.6229
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
illumin Holdings Inc. announces date for Fourth Quarter and Year-End 2025 Financial and Operating Results stocknewsapi
ILLMF
February 23, 2026 07:00 ET  | Source: illumin

TORONTO and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX:ILLM, OTCQB:ILLMF) (“illumin” or “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, announces that it will report its fourth quarter and year-end 2025 financial results before market open on Friday, March 13, 2026.

Investors and analysts are invited to join a live webcast on Friday, March 13, 2026, at 8:30 AM ET, where CEO Simon Cairns and Interim CFO Michael Amaro will discuss illumin’s Fourth Quarter and Year-End 2025 results, followed by a question-and-answer session.

Conference Call Details:

To register for the conference call webcast and presentation, please visit: https://events.illumin.com/q4-2025-earnings-call

Please connect at least 15 minutes prior to ensure time for any software download that may be needed to hear the webcast.

A recording of the conference call webcast will be available after the call by visiting the Company’s website at https://illumin.com/investor-information/.

About illumin:

illumin is evolving the digital advertising landscape by empowering marketers to achieve transformative results through its customer-centric approach. Featuring a unified canvas built around the open web, illumin lets brands and agencies seamlessly plan, build, and execute campaigns across the entire marketing funnel—connecting programmatic channels, email, and social media within a single platform. Headquartered in Toronto, Canada, illumin serves clients across North America, Latin America, and Europe. For more information, visit illumin.com.

For further information, please contact:

 Steve HoseinDavid Hanover Investor RelationsInvestor Relations – U.S. illumin Holdings Inc.KCSA Strategic Communications 416-369-4202212-896-1220 [email protected]@kcsa.com    Disclaimer in regard to Forward-looking Statements

Certain statements included herein constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Investors are cautioned not to put undue reliance on forward-looking statements. Except as required by law, the Company does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences stocknewsapi
GLUE
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to present, March 2, 2026, at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference (Miami, FL) – Filip Janku, M.D., Chief Medical Officer, to participate in a fireside chat, March 10, 2026, at 12:30 p.m. ET2026 Jefferies Biotech on the Beach Summit (Miami, FL) – March 11, 2026 Webcasts of the presentation and fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
[email protected]

Media
Cory Tromblee, Scient PR
[email protected]
2026-02-23 12:09 19d ago
2026-02-23 07:00 19d ago
Koryx Copper Announces Further Significant Drill Results at the Haib Copper Project, Southern Namibia stocknewsapi
KRYXF
Highlights 

Assay results reported for a further 13 drill holes for 4,965m of infill & expansion diamond drilling. Notable, selected drill intercepts from the holes include:   HM112: 602m @ 0.32% CuEq incl. 272m @ 0.44% CuEq incl. 40m @ 0.50% CuEq  HM121: 495m @ 0.31% CuEq incl. 284m @ 0.42% CuEq  HM117: 184m @ 0.51% CuEq (12 - 196m) incl. 16m @ 1.09% CuEq
16m @ 0.46% CuEq (268 - 284m)
30m @ 0.51% CuEq (300 - 330m)
     HM111: 64m @ 0.42% CuEq (154 - 218m) incl. 6m @ 0.74% CuEq  HM114: 66m @ 0.40% CuEq (28 - 94m)  HM115: 30m @ 0.52% CuEq (162 - 192m)
38m @ 0.63% CuEq (264 - to 302m)
  HM108: 18m @ 0.34% CuEq (24 - 42m)  HM109: 8m @ 0.60% CuEq (30 - 38m)
10m @ 0.42% CuEq (84 - 94m)
18m @ 0.42% CuEq (402 - 420m)    12 drill rigs active on site. Additional track mounted rigs (faster drilling & faster moves between holes) are being mobilised in order to accelerate the drill program.Updated geological modelling, grade estimation, inclusion of molybdenum (Mo) & gold (Au) by-products and the delineation of a large low grade halo has been completed. Updated MRE expected to be published shortly, reflecting these improvements. Drilling is ongoing with the objective of converting the entire MRE to Indicated status by mid-2026. Extensive metallurgical testwork and technical/infrastructure studies ongoing towards the planned publication of a PFS towards the end of 2026.

VANCOUVER, British Columbia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Koryx Copper Inc. (“Koryx” or the "Company") (TSX:KRY.V) (NSX:KYX) (OTCQB:KRYXF) is pleased to announce assay results from 13 drill holes (4,960m) received as part of the Phase 2 and 3 infill and expansion drill program for its 2026 exploration and project development strategy on the wholly-owned Haib Copper Project (“Haib” or the “Project”) in southern Namibia.

Haib is an advanced, large-scale open-pit sulphide Cu/Mo/Au porphyry project that is envisaged to produce at an average of 88,000tpa of Cu in concentrate over a 24-year mine life via a simple, scalable, open pit crushing/milling/flotation process. The Company's Preliminary Economic Assessment (“PEA”) dated 4 September 2025 demonstrated the project to be technically and economically feasible with attractive economics and a simple, scalable, long-life and low-cost development strategy undergoing rapid advancement.

Heye Daun, Koryx Copper’s President and CEO commented: “These latest assay results once-again demonstrate and confirm the size, grade and robust copper mineralization of the Haib deposit with some excellent, wide and very consistent intercepts across multiple areas of the envisaged open pit. The encouraging intersection widths and grades in the in-fill as well as step-out holes further strengthens the resource base. These results demonstrate the ongoing success of our drill program as we progress the technical work towards the highly anticipated PFS to be published in late 2026.”

Figure 1: Plan view indicating recent drill hole locations. Results indicated in black are shown on the long section below

Figure 2. Long section showing thirteen drillhole intersections relative to the model for Cu mineralization

Discussion of Drill Results

Thirteen drillholes are reported across the main mineralised zone at Haib, comprising three holes in Target 1, three in Target 2, five in Target 3 and two in Target 4. Four of these holes are classified as in-fill drillholes, designed to reduce sample spacing within known mineralisation, while the remaining nine are peripheral step-out holes intended to test the lateral extent of Cu mineralisation.

Results from the in-fill holes are better than anticipated, with both intersection widths and Cu grades exceeding expectations. The two holes drilled in the northern part of Target 3 and the two in the southeastern part of Target 2 tested conceptual grade extensions; although Cu grades were low, the implications for the mineral resource are considered negligible. The remaining step-out holes returned results ranging from slightly positive to highly encouraging, particularly in the eastern part of Target 1 and the southeastern sector of Target 3.

Table of Significant Intersections

Hole#ZoneFrom (m)To (m)Width (m)1Cu (%)Mo (ppm)Au (g/t)CuEq%2HM108Entire Hole0201.68201.680.17130.0260.19Main24.0042.0018.000.30100.0510.34HM109Entire Hole0470.52470.520.16880.0340.22Main30.0038.008.000.336260.0570.60Main42.0046.004.000.42520.0320.46Main84.0094.0010.000.40230.0110.42Main324.00328.004.000.54140.1270.64Main402.00420.0018.000.341240.0470.42HM110Entire Hole0208.19208.190.09110.0080.09HM111Entire Hole2.05222.87220.820.18330.0130.20Main122.00130.008.000.38360.0200.41Main154.00218.0064.000.37790.0210.42Including162.00168.006.000.65690.0330.70Including208.00214.006.000.70350.0370.74HM112Entire Hole0602.24602.240.261170.0250.32Main12.00102.0090.000.30380.0230.33Including16.0022.006.000.55470.0260.58Including92.00102.0010.000.451690.0330.54Main194.00200.006.000.48760.0300.53Main232.00504.00272.000.351750.0290.44Including266.00282.0016.000.541730.0330.63Including324.00330.006.000.54910.0240.59Including360.00400.0040.000.45780.0250.50Including438.00442.004.000.571010.0400.63Including466.00474.008.000.50130.1330.60HM113Entire Hole0635.6635.60.13380.0150.16Main64.0070.006.000.33610.0230.37Main76.0080.004.000.32390.0220.35Main92.0098.006.000.33250.0210.36Main344.00346.002.000.6050.0330.62Main370.00374.004.000.3860.0200.39Main376.00380.004.000.32120.0220.34Main404.00410.006.000.31130.0200.33Main442.00448.006.000.3290.0250.34Main484.00490.006.000.3530.0200.37Main526.00530.004.000.51480.0280.55HM114Entire Hole0317.04317.040.21370.0440.26Main28.0094.0066.000.34420.0520.40Including30.0034.004.000.77890.0790.86Main140.00150.0010.000.30740.0790.39Main196.00202.006.000.42360.0590.47Main218.00230.0012.000.301200.0390.37HM115Entire Hole0449.15449.150.22400.0310.26Main28.0032.004.000.48340.0480.53Main44.0048.004.000.33490.0310.37Main54.0060.006.000.42280.0450.46Main162.00192.0030.000.44420.0810.52Including170.00172.002.002.28790.4192.61Main264.00302.0038.000.551240.0480.63Including264.00268.004.001.442390.0701.57Including282.00286.004.001.24730.0471.31Including296.00302.006.000.922550.0561.06Main346.00356.0010.000.50260.0310.53Including352.00356.004.000.76230.0390.80Main404.00412.008.000.91590.0440.96Including406.00408.002.002.341390.0682.44HM116Entire Hole0222.6222.60.0460.0130.05HM117Entire Hole0428.29428.290.31430.0340.35Main12.00196.00184.000.46450.0470.51Including12.0028.0016.001.02460.0701.09Including36.0040.004.000.51460.0500.56Including48.0050.002.001.24160.0531.28Including54.0058.004.000.96520.0541.02Including90.0096.006.000.57380.0610.63Including102.00106.004.000.811000.0710.89Including142.00144.002.004.14210.1844.28Including150.00156.006.000.70200.0380.73Main268.00284.0016.000.42360.0310.46Including280.00282.002.000.97790.0441.03Main300.00330.0030.000.45830.0430.51Including312.00320.008.000.79990.0760.88HM118Entire Hole0183.63183.630.1590.0300.17HM120Entire Hole0530.38530.380.15700.0200.19Main348.00352.004.000.47250.0430.51HM121Entire Hole0494.59494.590.27420.0220.31Main92.00102.0010.000.3190.0310.34Main132.00136.004.000.50100.0380.53Main192.00476.00284.000.38630.0280.42Including224.00234.0010.001.08790.1211.19Including238.00242.004.001.19130.0491.23Including244.00254.0010.000.64310.0330.68Including266.00290.0024.000.51540.0340.55Including410.00420.0010.000.46100.0200.48 True widths are unknown. Widths are interval widths and not true widths. The reported intervals are calculated using the following parameters: Only Cu (%) was used to determine the intervals.The target composite grade is ≥0.30% Cu.Composites start and end with samples ≥0.30% Cu.Grades between 0.20% and 0.30% are included in interval but generally constitute <40% of the interval.Consecutive samples between 0.20% and 0.30% should be fewer than 5 samples (10m).Grades below 0.20% are included but generally constitute <20% of the interval.Consecutive grades <0.2% should be fewer than 2 samples (4m). Mineral Resource (MRE) copper equivalent (CuEq%) values have been calculated using commodity type and price considering the relevant recovery rate. The following metal prices were used Cu US$4.54/lb; Mo US$22.68/lb; Au US$4,000/oz along with the following recoveries indicated from test work, Cu 89%; Mo 65% and Au 50%. The CuEq was then calculated using CuEq = [(Cu grade/100 * 0.89 Cu recovery * 2204.62 * $4.54 Cu price/lb) + (Mo ppm/1000000 * 0.65 Mo recovery * 2204.62 * $22.68 Mo price/lb) + (Au grade * 0.50 Au recovery * 4000 Au price/oz / 31.1035)] / [0.89 Cu Recovery * 2204.62 * $4.54 Cu price/lb] Target 1 Results

HM114 was drilled in the southeastern part of Target 1 to reduce sample spacing in this area. Results are broadly consistent with expectations, with the known Cu mineralised zones successfully intersected; however, the upper high-grade zone from 28m downhole proved to be approximately 25m wider than anticipated. Of additional interest is an 8 m wide interval encountered at 88m downhole, averaging >0.1g/t Au, together with a further three samples between 140m and 312m returning grades exceeding 0.1g/t Au. Tungsten (W) is also present, with sporadic samples exceeding 100ppm and a peak value of 3,700 ppm recorded in a single sample.

HM115 is located 50m south of HM114 and returned results consistent with the current mineralisation model for Target 1, characterised by shallow-dipping zones. Two mineralised intervals intersected below 340m downhole (10m at 0.5% Cu and 8m at 0.91% Cu) exceed expectations in both thickness and grade. Gold grades are also elevated, with three samples between 110m and 172m downhole returning values of approximately 0.4 g/t Au.

HM117 is located 50m west of the two preceding boreholes and was drilled to reduce sample spacing in this area. Results are in line with expectations, with the upper 150m of the hole intersecting eight mineralised zones ranging from 2m to 16m in thickness and averaging between 0.5% and 4.1% Cu, the latter representing the highest Cu grade encountered to date at Haib. Deeper intersections of 16m at 0.42% Cu and 30m at 0.45% Cu represent significantly better-than-anticipated mineralisation at depth. Gold values remain elevated, with a 28 m wide zone from surface averaging just under 0.1 g/t Au.

Target 2 Results

HM108 was collared in the eastern part of Target 2 to test Cu mineralisation indicated by historical drilling. Copper grades are broadly in line with expectations; however, the higher-grade intersections around 120m downhole, suggested by historical data, proved to be both thinner and lower grade than predicted. Molybdenum is essentially absent, while gold is present in a 10m wide interval from 18m downhole, averaging just under 0.1 g/t Au.

HM118 was drilled on the eastern periphery of Target 2 to test the potential for resource extension in this area. The hole returned uniformly low Cu, Mo and Au grades, indicating that mineralisation at Haib does not extend into this location.

HM120 is located in the southern part of Target 2 and was drilled to define the boundary of higher-grade Cu mineralisation in this area. Although substantial portions of the hole returned Cu grades exceeding 0.2%, intersections grading above 0.3% Cu are limited. Molybdenum is present at elevated levels, with at least five discrete mineralised zones identified, the widest averaging 158ppm Mo over 88m. Gold is absent; however, tungsten values exceeding 100ppm are relatively common, including intersections of 2,470ppm W over 2m and 1,360ppm W over 2m.

Target 3 Results

HM110 and HM116 were drilled 87m apart on the same section in the eastern part of Target 3. Historical hole HM064, located approximately 140m south of HM110, intersected significant mineralisation, and these two holes were designed to test the up-dip extension of this mineralisation towards surface.

Both HM110 and HM116 returned no significant Cu or associated mineralisation, indicating that they lie outside the main mineralised envelope at Haib. A large-scale, interpreted sub-vertical shear zone has been mapped between HM110 and HM064. At Haib, shear zones are commonly associated with depletion of Cu, and it is therefore interpreted that the mineralisation intersected in HM064 terminates against or near this structure.

HM121 and HM111 were drilled north of, and on the same section as, previously reported holes HM090 and HM006 in the southeastern part of Target 3. HM090 and HM006 returned the widest near-surface high-grade Cu intersections (>1% Cu) encountered at Haib, and the new holes were designed to test the northern extension of this mineralisation.

Structural complexity is evident in this area, characterised by an east–west striking, broad, sub-vertical zone of intense alteration mapped between HM090 and HM121 and associated with depletion of Cu. This is reflected in the upper 88m of HM121, which averages only 0.06% Cu, with molybdenum absent. Beyond this depth and outside the alteration zone, Cu grades increase rapidly, culminating in a 284m interval of mineralisation averaging just under 0.4% Cu.

HM111, located 80 m north of HM121, returned comparable results. The upper 120 m of the hole averages 0.07% Cu, followed by a higher-grade interval of 64 m averaging 0.38% Cu. The hole was terminated while still in mineralisation and should be extended to fully define the depth extent of this zone. Spatial comparison of the high-grade intersections in HM006/HM090 and HM121/HM111 suggests that the zone of intense alteration is associated with a normal fault exhibiting up to approximately 150 m of vertical displacement.

HM112 was collared on the boundary between the Target 3 and Target 4 mineralised domains and drilled northwards to intersect the main Target 3 mineralisation at depth. Results indicate a broad zone from surface grading >0.3% Cu; however, Cu grades decrease to below 0.2% for the subsequent ~130m before defining a 17 m interval averaging 0.35% Cu. This includes higher-grade sub-intervals such as 16m at 0.54% Cu and 40m at 0.45% Cu.

Molybdenum is present at significant levels throughout this 172 m interval and extends into the footwall, averaging 196ppm Mo over 292m, with multiple samples exceeding 1,000ppm and a peak value of 5,200 ppm. Tungsten is also present, with a 32m interval averaging 450ppm W, including 4m at 1,640 ppm. Gold values are elevated locally, with a 2m sample returning 0.42 g/t Au.

Target 4 Results

HM109 was drilled well south of Target 4, progressing northwards to intersect previously identified Cu zones at depth. A shallow Cu zone exceeding 0.3% was confirmed, consistent with earlier drilling results. Deeper extensions of Cu mineralization are present but occur as thinner intervals with lower grades. Molybdenum (Mo) is notably elevated, averaging 279ppm from surface over 76m, including a high-grade interval of 8 m at 1,007 ppm. While the average Cu grade of this first 76m is 0.22%, these Mo grades raise the CuEq to 0.35% over this interval. Starting at a downhole depth of 26m, Au mineralization averages 0.15g/t over 10 m, with one sample returning 0.52g/t. Additional Au assays above 0.2g/t were also encountered at greater depths.

HM113, located 75m east of HM109, was drilled for the same objectives. Results are broadly comparable to HM109, though Cu grades are more continuous, averaging between 0.25–0.30%. Ten mineralized zones, ranging from 2m to 6m in width, returned grades of 0.30–0.35% Cu. These results indicate a reduction in grade with depth within the shallower Cu zones of Target 4. Molybdenum (Mo) is also present at elevated levels, with a 92 m interval from 24m downhole averaging 144 ppm.

Updated Drill Program

The drill program has been planned to achieve a comprehensive conversion of all mineral resources from the Inferred to the Indicated category resource in order for all of the material to qualify for the PFS study update in the second half of 2026. This entire drill program comprises 55,000m to be completed by the end of July 2026 to allow time for the assaying and updated resource modelling in 2026 Q3.

Quality Control

All drill core was logged, photographed, and cut in half with a diamond saw. Half of the core was bagged and sent to ALS Laboratories Ltd. in Johannesburg, South Africa for analysis (SANAS Accredited Testing Laboratory, No. T0387) and ActLabs in Canada, while the other half was quartered with one quarter archived and stored on site for verification and reference purposes while the other quarter will be used for metallurgical test work. 33 elements are analysed by Induced Coupled Plasma (ICP) utilizing a 4-acid digestion and gold is assayed for using a 30g fire assay method. Duplicate samples, blanks, and certified standards are included with every batch and are actively used to ensure proper quality assurance and quality control (“QA/QC”) The QA/QC frequency is 1 in 20 for each of blanks, duplicates and standards. 

Qualified Person

Mr. Dean Richards Pr.Sci.Nat., MGSSA – BSc. (Hons) Geology is the Qualified Person for the Haib Copper Project and has reviewed and approved the scientific and technical information in this news release and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr. Sci. Nat. No. 400190/08). Mr. Richards is independent of the Company and its mineral properties and is a Qualified Person for the purposes of National Instrument 43-101.

About Koryx Copper Inc.

Koryx Copper Inc. is a Canadian copper development Company focused on advancing the 100% owned Haib Copper Project in Namibia whilst also building a portfolio of copper exploration licenses in Zambia. Haib is a large, advanced (PEA-stage) copper/molybdenum porphyry deposit in southern Namibia with a long history of exploration and project development by multiple operators. More than 80,000m of drilling has been conducted at Haib since the 1970’s with significant exploration programs led by companies including Falconbridge (1964), Rio Tinto (1975) and Teck (2014). Extensive metallurgical testing and various technical studies have also been completed at Haib to date.

Additional studies are underway aiming to demonstrate Haib as a future long-life, low-cost, low-risk open pit, sulphide flotation copper project with the potential for additional copper production from heap leaching. Haib has a current mineral resource of 511Mt @ 0.33% Cu and 51 ppm Mo for 1,668kt of contained copper and 25.9kt contained Mo in the Indicated category and 308.9Mt @ 0.31% Cu and 40 ppm Mo for 949Mt of contained copper and 12.4kt contained Mo in the Inferred category (0.15% Cu cut-off).

Mineralization at Haib is typical of a porphyry copper deposit and it is one of only a few examples of a Paleoproterozoic porphyry copper deposit in the world and one of only two in southern Africa (both in Namibia). Due to its age, the deposit has been subjected to multiple metamorphic and deformation events but still retains many of the classic mineralization and alteration features typical of these deposits. The mineralization is dominantly chalcopyrite with minor bornite and chalcocite present and only minor secondary copper minerals at surface due to the arid environment.

Further details of the Haib Copper Project are available in the corresponding technical report titled, “Preliminary Economic Assessment of the Haib Copper Project, Namibia, National Instrument 43-101 Technical Report” dated effective September 4, 2025 (the "Technical Report"). The Technical Report and other information is available on the Company's website at www.koryxcopper.com and under the Company's profile on SEDAR+ at www.sedarplus.ca.

Additional information is also available by contacting the Company:

Julia Becker
Corporate Communications
[email protected]
+1-604-785-0850

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the use of proceeds from the Company's recently completed financings and the future or prospects of the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect ", "is expected ", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management discussion and analysis. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/801b97a6-3592-49aa-b5eb-59624c14a13b

https://www.globenewswire.com/NewsRoom/AttachmentNg/8505bfce-44ce-4d73-aae4-6f306af66655